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Abstract 
 
Background: Advanced chronic kidney disease is common in older people, and is frequently 
accompanied by metabolic acidosis. Oral sodium bicarbonate is used to treat this acidosis, but 
evidence is lacking on whether this provides a net gain in health or quality of life for older 
people. 
 
Objectives: To determine whether oral bicarbonate therapy improves physical function, 
quality of life, markers of renal function, bone turnover and vascular health compared to 
placebo in older people with chronic kidney disease and mild acidosis, to assess the safety of 
oral bicarbonate, and to establish whether oral bicarbonate therapy is cost-effective in this 
setting. 
 
Design: Parallel group, double-blind, placebo-controlled randomised trial. 
 
Setting: Nephrology and geriatric medicine outpatient departments in 27 UK hospitals 
 
Participants: Adults aged 60 years and over with advanced chronic kidney disease 
(glomerular filtration rate category 4 or 5, not on dialysis), with serum bicarbonate 
concentrations <22 mmol/L. 
 
Interventions: Eligible participants were randomised 1:1 to oral sodium bicarbonate or 
matching placebo. Dosing started at 500 mg thrice daily, increased to 1 g thrice daily if serum 
bicarbonate concentrations were <22 mmol/L at three months. 
 
Main outcome measures: The primary outcome was the between-group difference in the 
Short Physical Performance Battery at 12 months, adjusted for baseline. Other outcome 
measures included generic and disease-specific health-related quality of life, anthropometry, 
six-minute walk speed, grip strength, renal function, markers of bone turnover, blood 
pressure and B-type natriuretic peptide. All adverse events were recorded, including 
commencement of renal replacement therapy. For the health economic analysis, the 
incremental cost per quality-adjusted life year was the main outcome. 
 
4 
 
Results: 300 participants were randomised, 152 to bicarbonate and 148 to placebo. The mean 
age was 74 years and 86 (29%) were female. Adherence to study medication was 73% in both 
groups. 220 (73%) of participants were assessed at the 12 month visit. No significant 
treatment effect was evident for the Short Physical Performance Battery at 12 months (-0.4 
points; 95%CI -0.9 to 0.1, p=0.15). No significant treatment benefit was seen for any of the 
secondary outcomes. Adverse events were more frequent in the bicarbonate arm (457 versus 
400). Time to commencing renal replacement therapy was similar in both groups (HR 1.22, 
95% CI 0.74 to 2.02, p=0.43).  Health economic analysis showed higher costs and lower 
quality of life in the bicarbonate arm at one year with additional costs of £564 (95% CI £88 to 
1154) and quality-adjusted life years difference of -0.05 (95% CI -0.08 to -0.01); placebo 
dominated bicarbonate under all sensitivity analyses for incremental cost-effectiveness. 
 
Limitations: The trial population was predominantly white and male, limiting 
generalisability. The increment in serum bicarbonate concentrations achieved was small, and 
benefit from larger doses of bicarbonate cannot be excluded. 
 
Future work: Once other current trials of bicarbonate therapy in chronic kidney disease are 
complete, an individual-participant meta-analysis would be helpful to delineate any 
subgroups or treatment regimens more likely to give benefit. 
 
Conclusions: Oral sodium bicarbonate did not improve a range of health measures in people 
aged 60 and over with chronic kidney disease category 4 or 5 and mild acidosis, and is 
unlikely to be cost-effective for use in the NHS in this patient group. 
 
Trial registration: ISRCTN09486651. European Clinical Trials Database (EudraCT) number 
2011-005271-16 
 
Funding: National Institute for Health Research Health Technology Assessment programme 
(reference 10/71/01). 
 
Word count: 547 
  
5 
 
Contents 
Abstract ...................................................................................................................................... 3 
List of tables............................................................................................................................. 10 
List of figures ........................................................................................................................... 12 
List of abbreviations................................................................................................................. 16 
Plain English summary ............................................................................................................ 18 
Scientific summary .................................................................................................................. 19 
Chapter 1. Introduction ............................................................................................................ 25 
Background and rationale for the trial.................................................................................. 25 
Review of existing trial evidence ......................................................................................... 27 
Key findings from the systematic review: ........................................................................ 27 
Imperative for the current trial ............................................................................................. 29 
Trial objectives* ................................................................................................................... 30 
Chapter 2. Trial Design ............................................................................................................ 31 
Participants ........................................................................................................................... 31 
Target population for the trial ........................................................................................... 31 
Inclusion and exclusion criteria ........................................................................................ 31 
Trial intervention and comparator ........................................................................................ 32 
Outcome measures ............................................................................................................... 32 
Primary outcome............................................................................................................... 32 
Secondary outcomes ......................................................................................................... 32 
Health economic outcomes ............................................................................................... 34 
Sample size calculation ........................................................................................................ 34 
Chapter 3. Methods .................................................................................................................. 36 
Regulatory approvals............................................................................................................ 36 
Participants ........................................................................................................................... 36 
Site participation ............................................................................................................... 36 
Participant identification................................................................................................... 36 
Recruitment process.......................................................................................................... 37 
Washout arrangements...................................................................................................... 37 
Randomisation and treatment allocation .............................................................................. 37 
Unmasking ........................................................................................................................ 38 
Intervention and comparator ................................................................................................ 38 
Uptitration ......................................................................................................................... 38 
Returned medication and tablet counting ......................................................................... 38 
6 
 
Data management ................................................................................................................. 40 
Safety reporting .................................................................................................................... 40 
Trial Oversight Committees ................................................................................................. 41 
Patient and public involvement  ........................................................................................ 41 
Important changes to the trial design and conduct after trial commencement ..................... 41 
Re-estimation of sample size................................................................................................ 43 
Statistical analysis ................................................................................................................ 43 
Health Economic analysis .................................................................................................... 44 
Chapter 4. Clinical Effectiveness results ................................................................................. 45 
Recruitment .......................................................................................................................... 45 
Flow of participants through the trial ................................................................................... 45 
Participant baseline characteristics....................................................................................... 47 
Adherence and effect of intervention on serum bicarbonate................................................ 49 
Primary outcome .................................................................................................................. 50 
Subgroup analyses ............................................................................................................ 51 
Effect of adherence on primary outcome.......................................................................... 51 
Secondary outcomes............................................................................................................. 53 
Physical function .............................................................................................................. 53 
Anthropometry.................................................................................................................. 53 
Quality of life.................................................................................................................... 57 
Renal function................................................................................................................... 58 
Vascular health ................................................................................................................. 61 
Bone and mineral metabolism .......................................................................................... 62 
Other blood markers ......................................................................................................... 65 
Adverse events ..................................................................................................................... 67 
Need for renal replacement therapy (RRT) ...................................................................... 69 
Deaths ............................................................................................................................... 70 
Falls................................................................................................................................... 70 
Meta-analysis of outcomes with BiCARB data included..................................................... 71 
Chapter 5. Cost effectiveness results ....................................................................................... 73 
Chapter 6. Discussion .............................................................................................................. 96 
Key findings ......................................................................................................................... 96 
Results in context ................................................................................................................. 97 
Generalisability and limitations to generalisability.............................................................. 98 
Other limitations................................................................................................................... 99 
7 
 
Strengths ............................................................................................................................. 100 
Chapter 7. Conclusions .......................................................................................................... 101 
Implications for healthcare ................................................................................................. 101 
Suggestions for future research .......................................................................................... 101 
Acknowledgements ................................................................................................................ 103 
References .............................................................................................................................. 107 
Appendices............................................................................................................................. 115 
Appendix 1. Search strategy for systematic review – MedLine search ............................. 115 
Appendix 2: Systematic Review findings .......................................................................... 116 
Appendix 3. List of secondary outcomes in the BiCARB trial and details of tests used ... 121 
Appendix 4. Recruitment ................................................................................................... 124 
Appendix 5: Unit costs for health economic analysis ........................................................ 126 
Appendix 6. Health economic sensitivity analyses ............................................................ 130 
 
 
  
8 
 
List of tables 
Number Title Page 
1 List of secondary outcomes in the BiCARB trial 29 
2 Baseline characteristics of randomised participants 43 
3 Intervention uptitration and adherence 45 
4 Primary outcome (Short physical performance battery at 12 months) 47 
5 Secondary outcomes: measures of physical function and 
anthropometry  
49 
6 Secondary outcomes: Measures of quality of life 52 
7 Secondary outcomes: Measures of renal function and associated 
biochemistry 
54 
8 Secondary outcomes: Markers of vascular health 56 
9 Secondary outcomes: Markers of bone and mineral metabolism 58 
10 Secondary outcomes: Other blood markers 60 
11 Adverse events by System Order Class (SOC) 62 
12 Selected key adverse outcomes of interest  63 
13 Mean resource use and costs per patient over 12 months follow-up 69 
14 Mean resource use and costs per patient over 24 months follow-up 71 
15 Mean resource use and costs per patient over 24 months follow-up 
(complete cases and all participants starting renal replacement 
therapy during the trial) 
73 
16 Mean EQ-5D values and QALYs over 12 months follow-up, by 
randomised group 
75 
17 Mean EQ-5D values and QALYs over 24 months follow-up, by 
randomised group 
76 
18 Mean ICECAP values over 12 months follow-up, by randomised 
group 
76 
19 Mean ICECAP values over 24 months follow-up, by randomised 
group 
77 
20 Mean life satisfaction values over 12 months follow-up, by 
randomised group 
78 
Formatted Table ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
9 
 
21 Mean life satisfaction values over 24 months follow-up, by 
randomised group 
78 
22 Adjusted mean incremental costs, incremental QALYs, and 
incremental cost-effectiveness ratio between sodium bicarbonate vs 
placebo 
79 
Appendix 1 
Table 
Search strategy for systematic review – MedLine search 103 
Appendix 2 
Table 
Systematic review findings: Characteristics of included studies 104 
Appendix 3 
Table 
List of secondary outcomes in the BiCARB trial and details of tests 
used 
109 
Appendix 4 
Table 
Recruitment by site 113 
Appendix 5 
Table 
Unit costs for health economic analysis 114 
 
  
Formatted: Font: (Default) Times New Roman, 12 pt
Formatted: Normal,  No bullets or numbering
Formatted: Centered
Formatted: Font: (Default) Times New Roman, 12 pt
Formatted: Normal,  No bullets or numbering
Formatted: Centered
Formatted: Centered
Formatted: Centered
Formatted: Centered
Formatted: Centered
Formatted: Centered
10 
 
1.  
List of figures 
Number Title Page 
1 Flow of participant visits and activities through the trial 35 
2 CONSORT diagram 42 
3 Change in bicarbonate concentration relative to baseline 46 
4 Subgroup analyses for primary outcome 47 
5 Change in estimated glomerular filtration rate relative to baseline  55 
6 Change in blood pressure relative to baseline  57 
7 Time to commencement of renal replacement therapy 64 
8 Time to death 65 
9 Meta-analysis: Difference in serum bicarbonate (any timepoint) 66 
10 Meta-analysis: Difference in serum bicarbonate (one year follow 
up only) 
66 
11 Meta-analysis: Difference in estimated GFR (any timepoint) 66 
12 Meta-analysis: Difference in estimated GFR (one year follow up 
only) 
67 
13 Meta-analysis: Difference in systolic blood pressure (any 
timepoint) 
67 
14 Meta-analysis: Difference in weight (any timepoint) 67 
15 Meta-analysis: Difference in mid-arm muscle circumference (any 
timepoint) 
67 
16 Scatterplot and cost-effectiveness acceptability curve of 
incremental cost difference and incremental QALY difference 
between randomised groups 
83 
17 Sensitivity analyses of incremental cost difference and incremental 
QALY or ICECAP difference between randomised groups – 12 
months 
85 
Appendix 2 
Figure 1 
Quality assessment of included studies 106 
Appendix 2 
Figure 2 
Meta-analysis before BicARB: Serum bicarbonate (any timepoint) 107 
Formatted Table ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
Formatted ...
11 
 
Appendix 2 
Figure 3 
Meta-analysis before BicARB: Serum bicarbonate (1 year follow-
up only) 
107 
Appendix 2 
Figure 4 
Meta-analysis before BicARB: Estimated GFR (any timepoint) 107 
Appendix 2 
Figure 5 
Meta-analysis before BicARB: Estimated GFR (1 year follow-up 
only) 
108 
Appendix 2 
Figure 6 
Meta-analysis before BicARB: Systolic blood pressure (any 
timepoint) 
108 
Appendix 2 
Figure 7 
Meta-analysis before BicARB: Weight (any timepoint) 108 
Appendix 2 
Figure 8 
Meta-analysis before BicARB: Mid-arm muscle circumference 
(any timepoint) 
108 
Appendix 4 
Figure 1 
Monthly recruitment rate 112 
Appendix 4 
Figure 2 
Cumulative recruitment 112 
Appendix 6 
Figure 1 
Sensitivity analyses of incremental cost difference and incremental 
QALY or ICECAP difference between randomised groups – 24 
months 
118 
Appendix 6 
Figure 2 
Sensitivity analyses of incremental cost difference and incremental 
life satisfaction difference between randomised groups – 12 and 24 
months 
120 
Appendix 6 
Figure 3 
Sensitivity analyses of incremental cost difference and incremental 
QALY or ICECAP difference between randomised groups – 
Complete cases over 24 months follow-up and all participants 
starting renal replacement therapy during the trial   
122 
1. Flow of participant visits and activities through the trial 
2. CONSORT diagram 
3. Change in bicarbonate concentration relative to baseline 
4. Subgroup analyses for primary outcome 
5. Change in estimated glomerular filtration rate relative to baseline  
6. Change in blood pressure relative to baseline  
7. Time to commencement of renal replacement therapy 
Formatted: Centered
Formatted: Centered
Formatted: Centered
Formatted: Centered
Formatted: Centered
Formatted: Centered
Formatted: Centered
Formatted: Centered
Formatted Table
Formatted: Font: (Default) Times New Roman, 12 pt
Formatted: Normal,  No bullets or numbering
Formatted: Centered
Formatted: Font: (Default) Times New Roman, 12 pt
Formatted: Normal,  No bullets or numbering
Formatted: Centered
Formatted: Font: (Default) Times New Roman, 12 pt
Formatted: Normal,  No bullets or numbering
Formatted: Centered
Formatted: Normal, Line spacing:  single,  No bullets or
numbering
Formatted: Font: (Default) +Body (Calibri), 11 pt
12 
 
  
13 
 
List of abbreviations 
1,25OHD 1,25-dihydroxyvitamin D 
25OHD 25-hydroxyvitamin D 
AE  Adverse Event 
ANOVA ANanlysis Of VAriance 
BNP  B-type Natriuretic Peptide 
BP  Blood Pressure 
bsALP  Bone-specific Alkaline Phosphatase 
CI  Confidence Interval 
CKD  Chronic Kidney Disease 
CONSORT CONolidated Standards Of Reporting Trials 
CTIMP Clinical Trial of Investigational Medicinal Product 
CTU  Clinical Trials Unit 
DEXA  Dual Energy X-ray Absorptimetry 
DMC  Data Monitoring Committee 
eGFR  estimated Glomerular Filtration Rate 
EQ-5D EuroQoL 5-dimension tool 
EudraCT European Clinical Trials Database 
GCP  Good Clinical Practice 
GP  General Practitioner 
HbA1c Haemoglobin A1c (glycosylated Haemoglobin) 
HEAP  Health Economic Analysis Plan 
HR  Hazard Ratio 
HTA  Health Technology Assessment 
ICECAP Investigating Choice Experiments for the preferences of older people 
CAPability tool 
IL  Interleukin 
KDIGO Kidney Disease – Improving Global Outcomes 
KDQoL Kidney Disease Quality of Life tool 
MAMC Mid-arm Muscle Circumference 
MCID  Minimum Clinically Important Difference 
14 
 
MDRD Modification of Diet in Renal Disease 
MedDRA Medical Dictionary for Regulatory Activities 
MHRA Medicines and Healthcare products Regulatory Agency 
MTC  Mid-thigh Circumference 
NHS  National Health Service 
NICE  National Institute for health and Care Excellence 
NIHR  National Institute for Health Research 
PTH  Parathyroid Hormone 
QALY  Quality Adjusted Life Year 
QP  Qualified Person 
RCT  Randomised Controlled Trial 
RRT  Renal Replacement Therapy 
SAE  Serious Adverse Event 
SAP  Statistical Analysis Plan 
SAS  Statistical Analysis Software 
SOC  System Order Class 
SPPB  Short Physical Performance Battery 
TMG  Trial Management Group 
TNF  Tumour Necrosis Factor 
TRACP-5b Tartrate-Resistant Acid Phosphatase type 5b 
TRuST  Tayside Randomisation SysTem 
TSC  Trial Steering Committee 
TSF  Triceps Skinfold Thickness 
TSH  Thyroid Stimulating Hormone 
 
 
  
15 
 
Plain English summary 
Patients with advanced chronic kidney disease often have excessive levels of acid in their 
blood (acidosis). Acidosis has been associated with a range of other problems which 
particularly affect patients with chronic kidney disease, including weaker muscles, weaker 
bones, worse blood vessel health, and kidney disease that worsens more quickly. For decades, 
acidosis has been treated with sodium bicarbonate tablets (the ingredient found in baking 
soda) to neutralise the excess acid. However, sodium bicarbonate is awkward to take, may 
cause side effects, and may increase blood pressure. 
 
To clarify whether sodium bicarbonate caused an overall improvement in health, we carried 
out a study involving 300 people aged 60 and over with advanced chronic kidney disease and 
mild acidosis. Half received sodium bicarbonate capsules and half received dummy capsules 
(placebo), for up to two years. The treatments were chosen randomly by a computer, and 
neither the participants, their doctors, nor the research team knew the treatment until the end 
of the study. We measured physical function (walking speed, ability to stand from a chair, 
balance), alongside quality of life, kidney function, bone and blood vessel health, side effects 
and health service use over two years. 
 
We found that sodium bicarbonate did not improve physical function or quality of life 
compared to the group who got placebo. Sodium bicarbonate also did not improve kidney 
function, bone health or blood vessel health compared to placebo. More people had side 
effects from sodium bicarbonate than from placebo, although blood pressure was the same in 
both groups. Healthcare costs were higher in the group who received sodium bicarbonate than 
in the placebo group. We conclude that oral sodium bicarbonate did not significantly improve 
health measures when compared to placebo for older people (aged over 60 years) with 
advanced chronic kidney disease, associated with mild acidosis. 
 
Word count: 300 
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Scientific summary 
Background 
Chronic kidney disease (CKD) becomes increasingly common with advancing age, with 
approximately 2% of the population aged 70 years and over suffering from advanced 
(glomerular filtration rate [GFR] category 4 or 5) chronic kidney disease. Advanced CKD is 
often accompanied by metabolic acidosis, due to inability of the kidneys to excrete sufficient 
excess acid. Acidosis has been associated with a range of adverse health outcomes in patients 
with CKD, including worse cardiovascular health, weaker bones, weaker muscles and more 
rapid progression of kidney disease. As a result, oral sodium bicarbonate has been used for 
decades to counteract metabolic acidosis. Few trials have tested whether sodium bicarbonate 
is effective at countering these adverse outcomes. Sodium bicarbonate also carries risks of 
gastrointestinal side effects, is awkward for patients to take, and there are concerns that the 
sodium content might increase blood pressure or fluid overload. These issues are of particular 
relevance for older people, who make up the majority of people in the UK with advanced 
kidney disease, and are most likely to suffer side effects by dint of coexisting multimorbidity 
and polypharmacy. 
  
Objectives 
The primary objective of the BiCARB trial was to determine whether oral bicarbonate 
therapy improves physical function compared to placebo in older people with CKD and mild 
acidosis.  
 
The secondary objectives were: 
a) to determine whether oral bicarbonate therapy improves health-related quality of life 
compared to placebo;  
b) to compare the impact of oral bicarbonate therapy against placebo on biochemical markers 
of CKD;  
c) to assess whether use of oral bicarbonate therapy is associated with an excess of adverse 
events compared with placebo;  
d) to estimate the cost-effectiveness of using oral bicarbonate therapy compared with 
placebo; and  
e) to assess the effect of oral bicarbonate therapy compared with placebo on bone turnover 
and vascular health as assessed by biochemical markers. 
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Methods 
The study was a parallel group, double-blind, placebo-controlled randomised trial. 
Participants were recruited from nephrology and geriatric medicine outpatient departments in 
UK hospitals. Participants were eligible for inclusion if they were aged 60 years and over 
with advanced CKD (GFR category 4 or 5, not on dialysis), with serum bicarbonate 
concentrations <22 mmol/L. Participants were excluded if they were currently taking 
bicarbonate, had a diagnosis of renal tubular acidosis, were taking bisphosphonate drugs, 
were on or would soon start renal replacement therapy, were terminally ill, could not give 
written informed consent, had uncontrolled hypertension or decompensated chronic heart 
failure, were participating in another clinical trial or were allergic to sodium bicarbonate 
tablets or lactose (used as an excipient in the tablets). Eligible participants were randomised 
1:1 to oral sodium bicarbonate tablets or identical matching placebo tablets using a web-
based randomisation system to conceal allocation. Dosing started at 500 mg three times a 
day, and was increased to 1 g three times a day if serum bicarbonate concentrations were <22 
mmol/L at the three month visit. 
 
Outcomes were collected at baseline, three, six, 12 and 24 months. The primary outcome was 
the between-group difference in the Short Physical Performance Battery (a measure of lower 
limb strength and balance that predicts future disability, need for care and death) at 12 
months, adjusted for baseline. The initial sample size calculation estimated that 380 
participants were required to detect a one-point difference between groups in the Short 
Physical Performance Battery at 12 months with 90% power, assuming a standard deviation 
of 0.6, an alpha of 0.05 and a dropout rate of 10% every six months. Sample size re-
estimation prior to closing recruitment indicated that 300 participants would have 87% power 
to detect the one-point difference in the SPPB after adjusting for baseline values. Secondary 
outcome measures included generic (EuroQoL EQ5D) and disease-specific (Kidney Disease 
Quality of Life) health-related quality of life questionnaires, anthropometry (weight, mid-arm 
muscle circumference, triceps skinfold thickness, mid-thigh circumference), physical 
performance (six-minute walk speed, grip strength), renal function measured using creatinine, 
cystatin C, and urinary albumin/creatinine ratio; markers of bone turnover and mineral 
metabolism (serum calcium, phosphate, bone-specific alkaline phosphatase, tartrate-resistant 
acid phosphatase 5b, 25-hydroxyvitamin D and 1,25 hydroxyvitamin D), vascular health 
(blood pressure, B-type natriuretic peptide and serum cholesterol), and other relevant 
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biochemical markers including haemoglobin, thyroid stimulating hormone, and serum 
albumin. All adverse events were recorded, including commencement of renal replacement 
therapy. Falls were recorded prospectively by self-completed falls diaries. For the health 
economic analysis, information on health and social care use was collected at each follow up 
visit, and was combined with quality of life measures to derive the incremental cost per 
quality-adjusted life year. 
 
Analyses were prespecified in statistical analysis plans and conducted by intention-to-treat. 
The primary outcome (between group difference in the SPPB at 12 months) was analysed 
using linear mixed models, adjusted for baseline measurements, minimisation variables (age, 
sex, and stage of CKD), and a random effect variable for recruitment site. Preplanned 
subgroup analyses were conducted for age, sex, baseline CKD stage, baseline bicarbonate 
level, baseline SPPB and high vs low adherence. Secondary outcomes were analysed using 
repeated measures models, adjusted for baseline values and minimisation variables as above. 
Time-to-event analyses (time to death, time to commencing renal replacement therapy) were 
conducted using Cox proportional hazards models adjusted for minimisation variables as 
above. For all analyses, a two-sided p value of <0.05 was taken as significant with no 
adjustment for multiple testing. For the health economic analysis, a cost-utility analysis was 
undertaken which involved estimation of the incremental costs and incremental effects 
measured using Quality Adjusted Life Years, QALYs, based on responses to the EQ-5D-3L 
instrument.  Estimation was performed using generalised linear regression modelling, with 
adjustment for skewed data and for baseline differences in cost, EQ-5D-3L and other patient 
characteristics (age, gender, chronic kidney disease stage). Non-parametric bootstrap methods 
were used for calculating confidence intervals around cost and QALY differences.  Cost 
effectiveness acceptability curves were employed to show the probability that bicarbonate 
therapy was cost effective for different values of willingness to pay per additional QALY. 
 
Results 
We randomised 300 participants from 27 UK nephrology and geriatric medicine outpatient 
centres between May 2013 and February 2017. One hundred and fifty-two were allocated to 
bicarbonate and 148 to placebo. The mean age was 74 years and 86 (29%) were female. The 
Short Physical Performance Battery at baseline was 8.0 and 8.1 points in the bicarbonate and 
placebo arms, denoting substantially impaired physical performance. Adherence to study 
medication was 73% in both groups. 116 (76%) and 104 (70%) of participants were assessed 
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at the 12 month visit in the bicarbonate and placebo groups respectively. The mean dose of 
bicarbonate prescribed was 1.88 grams per day, with a mean dose of 1.39 grams per day 
ingested. Bicarbonate concentrations were an average of 1.1 mmol/L higher in the 
bicarbonate group than in the placebo group over the whole course of the trial. 
 
 No significant treatment effect was evident for the primary outcome of the between-group 
difference in the Short Physical Performance Battery at 12 months (-0.4 points; 95% CI -0.9 
to 0.1, p=0.15). Very similar results were found in sensitivity analyses using multiple 
imputation of missing data. Subgroup analyses showed no significant difference in treatment 
effect based on age (<75 vs >=75), sex, baseline CKD category (4 vs 5), baseline bicarbonate 
level (<18 vs >=18 mmol/L), or baseline SPPB (<10 vs >=10). Participants with adherence 
above and below the prespecified 80% threshold showed similar treatment effects on the 
SPPB at 12 months (adherence >80%: -0.6 points [95% CI -1.3 to 0.1], adherence <=80%: 
0.0 points [95% CI -0.7 to 0.7]). These results excluded the minimum clinically important 
improvement for the SPPB (of one point) with a high degree of confidence. 
 
No significant treatment benefit was seen for any of the secondary outcomes including 
quality of life, anthropometry, NT-pro-B type natriuretic peptide and markers of bone 
turnover and mineral metabolism. Of particular note, there was no significant treatment effect 
on estimated GFR (repeated measures treatment effect 0.6 ml/min/1.73m2 [95% CI -0.8 to 
2.0, p=0.39). Measures of physical performance were worse in the bicarbonate arm than in 
the placebo arm when considered across all visits; SPPB treatment effect -0.6 points (95% CI 
-1.0 to -0.1, p=0.02); six minute walk treatment effect -33 metres (95% CI -62 to -4, p=0.02); 
handgrip strength -1.5kg (95% CI -2.8 to -0.2, p=0.03). Blood pressure was no higher in the 
bicarbonate arm (repeated measures treatment effect for systolic blood pressure 0mmHg 
[95% CI -4 to 3, p=0.93]; diastolic blood pressure -1mmHg [95% CI -3 to 1, p=0.16]) 
 
Adverse events were more frequent in the bicarbonate arm (457 versus 400), driven in part by 
higher rates of gastrointestinal adverse events, but also by higher rates of cardiovascular and 
respiratory adverse events. Thirty-three participants commenced renal replacement therapy 
(dialysis or transplantation) in each group during the trial. Time to commencing renal 
replacement therapy was similar in both groups (HR 1.22, 95% CI 0.74 to 2.02, p=0.43). 
There were 15 deaths in the bicarbonate arm, compared to 11 in the placebo arm. The time to 
death was not significantly different between the two arms (HR 1.30, 95% CI 0.60 to 2.83, 
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p=0.51). There were more falls amongst participants in the bicarbonate arm (49 vs 39); fall 
rates per participant were not significantly different in the two arms: bicarbonate 0.99 falls 
per year (95% CI 0.61 to 1.38); placebo 0.72 falls per year (95% CI 0.25 to 1.19) 
 
Health economic analysis showed higher costs and lower quality of life in the bicarbonate 
arm at one year, with additional costs of £564 (95% CI £88 to £1154) and QALY difference 
of -0.05 (95% CI -0.08 to -0.01).Health economic analysis showed lower quality of life and 
higher costs in the bicarbonate arm at one year (£1234 vs £807).  Similar differences were 
also found at two years follow-up.  In further analyses, the addition of the costs of renal 
replacement for renal replacement patients who were lost to follow-up led to a non-
significant additional cost of £809 amongst the bicarbonate group over 24 months (95% CI £ 
-4125 to £5412). A series of one-way sensitivity analyses were conducted (lower generic 
prescribing costs, lower cost per day, lower and higher dialysis costs, use of ICECAP values 
rather than EQ-5D and QALYs).  In all sensitivity analyses, patients in the placebo group 
were estimated to have lower costs and better quality of life.  Excluding dialysis patients who 
were lost to follow-up and their renal replacement costs, the probability of sodium 
bicarbonate being more cost-effective than placebo was close to zero in all analyses.  The 
inclusion of dialysis costs for patients who dropped out of the trial after commencement of 
dialysis led to non-significant additional costs amongst the bicarbonate patients, and the 
probability of sodium bicarbonate being more cost-effective was found to be between 15%-
20%. Placebo dominated bicarbonate under all sensitivity analyses for incremental cost-
effectiveness. 
 
Conclusions: Implications for healthcare: 
The results from this pragmatic, multicentre placebo-controlled trial suggest that at least for 
older patients with CKD category 4 and 5, 1.5 grams to 3 grams per day of oral bicarbonate 
did not produce any health benefits and may be associated with net harms. Whilst other 
indications for control of acidosis exist (for example high potassium concentrations), 
evidence from the current trial suggests that the additional cost, treatment burden and side 
effects of oral bicarbonate may not justify its routine use in older people with advanced CKD 
and mild acidosis.  
 
Suggestions for further research: 
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Other trials of bicarbonate are in progress. Once complete, an individual participant meta-
analysis should be conducted, examining the effects of bicarbonate therapy on physical 
function, quality of life, renal function and progression to renal replacement therapy, 
anthropometry, bone and vascular health. Such a meta-analysis should also seek to pool 
adverse events, particularly cardiovascular events, and should also seek to identify 
characteristics of those most likely to respond to bicarbonate therapy, if any. 
 
Depending on the results of meta-analyses, it may be necessary to formally test the 
effectiveness of bicarbonate therapy in other groups with CKD, for example younger patients, 
or those with lower serum bicarbonate concentrations, in further randomised controlled trials. 
Alternative methods to manage acidosis in advanced CKD need to be tested, either using 
different bicarbonate treatment strategies such as dose-titration to target, or novel methods of 
managing acidosis not relying on the use of bicarbonate. 
 
A final, broader recommendation is that there is a need to design and execute more trials like 
BiCARB, focussing on outcomes important to older patients, both in the field of chronic 
kidney disease, but also more widely in other organ-specific fields of clinical practice for 
older people. 
 
Trial registration:  
ISRCTN09486651. European Clinical Trials Database (EudraCT) number 2011-005271-16 
 
Systematic review registration:  
PROSPERO database, CRD42018112908 
 
Funding: National Institute for Health Research Health Technology Assessment programme 
(reference 10/71/01). 
 
Word count: 2091 
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Chapter 1. Introduction 
 
In 2010, the Health Technology Assessment (HTA) programme of the National Institute for 
Healthcare Research (NIHR) commissioned a randomised controlled trial (RCT) to address 
the clinical and cost effectiveness of oral sodium bicarbonate therapy for older people with 
advanced chronic kidney disease (CKD) and mild metabolic acidosis. This monograph 
reports the findings of the multicentre RCT conducted to address that brief. 
 
BiCARB was a large, multicentre RCT comparing whether oral sodium bicarbonate therapy 
was more effective than placebo at improving physical function and quality of life in patients 
aged 60 years and over with CKD glomerular filtration rate (GFR) categories 4 or 5 (<30 
mL/min/1.73 m2) and mild metabolic acidosis, not on renal replacement therapy. 
 
Background and rationale for the trial 
Chronic Kidney Disease (CKD) is common; 6.1% of the English population have an 
estimated glomerular filtration rate (eGFR) of <60 mL/min/1.73m2 (i.e. GFR category 3 to 5 
in the international CKD staging system),1 and rates in people age over 70 years are five 
times higher than this.2 Population-based estimates suggest a prevalence of severe CKD 
(eGFR 15-29mL/min/1.73 m2, equivalent to CKD category 4) of approximately 2% in those 
aged 70 years and over,3 and approximately 20% of such patients will have a degree of 
metabolic acidosis (often operationalised as a serum bicarbonate level <22mmol/L), with 
rates increasing as renal function declines.4 As discussed below, metabolic acidosis has been 
associated with multiple adverse outcomes including impaired bone health, vascular health, 
accelerated renal decline and worse physical function. The extent to which acidosis is causal 
for these phenomena, as opposed to associations being due to residual confounding by other 
unmeasured factors present in patients with CKD, remains unclear. 
 
Association of acidosis with progression of renal dysfunction 
Several studies have linked the presence of lower serum bicarbonate concentrations to 
accelerated decline in renal function.5,6 There is debate as to how much of these observed 
associations are due to low bicarbonate concentration independent of renal function. Recent 
pooled data from two large randomised controlled trials suggested that lower baseline 
bicarbonate concentrations correlate with faster decline in GFR and a higher chance of 
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reaching kidney failure, but also found that this association disappeared after adjusting for 
baseline GFR.7 In the Modification of Diet in Renal Disease (MDRD) Study cohort, serum 
bicarbonate was not associated with progression to end-stage renal failure or death after 
adjustment for baseline GFR.5 Conversely other studies have found that the association 
between low serum bicarbonate and accelerated decline in renal function remains even after 
adjustment for baseline GFR.8 
 
Association with cardiovascular disease 
In the cardiovascular system, acidosis has been associated with increased levels of endothelin 
and aldosterone, chronic inflammation, and endothelial dysfunction.9-11 There is a lack of 
evidence of an association between low serum bicarbonate and increased vascular events.7,12 
An elevated serum bicarbonate concentration may however be associated with deleterious 
outcomes, and concern persists that administration of the sodium load that accompanies 
bicarbonate administration could increase blood pressure.13 
 
Association with physical function 
Recent data suggests an association between lower serum bicarbonate concentrations and 
impaired physical function even in patients without advanced CKD.14 Importantly for older 
patients with CKD, low serum bicarbonate also predicts future onset of functional limitation 
(defined as difficulty walking a quarter of a mile or climbing ten steps) in older people. Those 
with serum bicarbonate <23 mmol/L were 1.6 times as likely to develop functional limitation 
as those with baseline serum bicarbonate of >=26 mmol/L, even after adjustment for the 
presence of CKD.15 Sarcopenia (the loss of muscle mass and strength) is common in 
advanced CKD, and may in part be driven by acidosis, which stimulates muscle proteolysis.16 
 
Association with bone health 
An acidic environment can have direct effects on the skeleton by increasing bone resorption 
whilst reducing osteoblastic bone formation. Other contributory pathological consequences 
include its indirect effects on parathyroid hormone (PTH) and/or vitamin D metabolism. 
Acidosis has been shown to affect PTH release as well as the cellular response to PTH and 
inhibits PTH-induced 1,25 (OH) vitamin D formation by suppressing 1-alpha hydroxylase 
activity.17 Acidosis produces an inflammatory state with the production of cytokines such as 
IL-6 and TNF-alpha which promote osteoclastic bone resorption. These abnormalities can 
exacerbate not only the bone and mineral abnormalities associated with CKD but can also 
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lead to osteoporosis. Bone mineral density is adversely affected by acidosis in CKD, although 
the effect on fracture rate remains unclear; few data exist on fracture rates in patients with 
CKD not undergoing dialysis.18-20 
 
Review of existing trial evidence 
As part of the preparation for this report, we have undertaken a systematic review to 
synthesise current trial evidence in this area. The search strategy for this systematic review is 
given in Appendix 1; details of included studies are given in Appendix 2 Table 1 and 
forest plots for the main meta-analysed outcomes are shown in Appendix 2 Figures 2 to 
8. The systematic review was registered on the PROSPERO database (CRD42018112908). 
Evidence available prior to completion of the BiCARB trial is discussed here and has been 
published along with the full methods;21 meta-analyses were then repeated with the addition 
of results from BiCARB and these results are discussed in Chapter 6. 
 
Key findings from the systematic review: 
A total of seven trials were eligible for inclusion,22-28 recruiting a total of 815 participants 
with CKD not on dialysis. Trial size ranged from 40 to 188 participants, mean age ranged 
from 40 to 65 years and follow-up ranged from three months to five years. Most trials 
included participants with a baseline bicarbonate concentration within the normal range (i.e. 
greater than 22mmol/L), and compared strategies of bicarbonate replacement (titration to 
target levels) rather than administering fixed bicarbonate doses. Quality of the trials was poor 
to moderate, with all seven trials failing to adequately mask participants and clinicians, and 
the effectiveness of masking of research teams being unclear in five of seven trials. 
 
The overall treatment effect on bicarbonate concentrations seen in the trials was a mean 
increase from supplementation of 3.4mmol/L (95% CI 1.9 to 4.9) Marked heterogeneity in 
the timepoints used for follow up makes comparison across trials challenging, but the 
treatment effect on bicarbonate concentrations at one year was 3.2mmol/L (2.0 to 4.3). 
Estimated GFR was modestly higher in the intervention groups than in the control groups at 
the last follow up timepoint (mean difference 3.1mL/min/1.73m2, 95% CI 1.3 to 4.9) but was 
not significantly different when confining analyses to one year outcomes only 
(1.4mL/min/1.73m2, 95% CI -0.7 to 3.4). Too few trials reported the rate of change of eGFR 
to meta-analyse this outcome. 
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Systolic blood pressure was modestly but significantly higher in the intervention groups 
compared to control overall (mean difference 2.1mmHg, 95% CI -1.0 to 5.2); one year 
comparisons could not be made. Body weight and mid-arm muscle circumference (a measure 
of lean body mass) showed small, nonsignificant improvements in meta-analysis from 
supplementation. No studies reported measures of physical performance or quality of life. 
Insufficient events were recorded to enable a judgement to be made about whether 
bicarbonate treatment reduced the risk of commencing dialysis or transplantation; one study 
recorded four participants commencing dialysis in the bicarbonate arm vs 22 in the control 
arm;23 another study recorded three participants commencing dialysis in the bicarbonate arm 
and four in the control arm.28 
 
In summary, existing data prior to the BiCARB trial do not shed light on whether bicarbonate 
therapy improves physical function or quality of life for older patients with CKD and 
acidosis; there is significant uncertainty as to whether bicarbonate therapy can improve or 
mitigate the decline in renal function seen in advanced CKD, and there is uncertainty as to 
whether bicarbonate therapy worsens blood pressure control and thus could increase the risk 
of cardiovascular events. 
 
Potential deleterious effects of bicarbonate 
Oral bicarbonate is inexpensive and has been used for many years. For some clinicians, the 
default position is to presume that the potential benefits are likely to exceed the risks of what 
is perceived to be a very safe intervention. Oral bicarbonate is not easy for patients to take - 
the tablets are large, and multiple tablets usually need to be taken each day. Older patients  
are more likely to have dysphagia or a dry mouth, and are already subject to polypharmacy. 
Sodium bicarbonate contains six mmol of sodium per 500 mg, and a typical daily dose in 
current nephrology practice is up to three grams per day – equivalent to the amount of sodium 
in 0.8 grams of table salt. Concerns persist that this sodium load may lead to increased blood 
pressure and fluid overload. An additional concern is that raising the blood pH, calcium 
phosphate may be more likely to precipitate out into blood vessel walls, worsening vascular 
calcification.29 Finally, gastrointestinal side effects (such as abdominal discomfort and 
bloating are listed in the Summary of Product Characteristics; likely a result of generation of 
carbon dioxide in the gut via interaction with stomach acid. 
 
Current guidelines 
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The introduction routine eGFR reporting by laboratories has increased the number of older 
patients diagnosed with CKD,30 and bicarbonate is often used to treat older people with low 
serum bicarbonate concentrations. Trial evidence to underpin the effectiveness and safety of 
this intervention is however lacking, and this lack of evidence is reflected in current 
guidelines, including Kidney Disease Improving Global Outcomes (KDIGO)31 and UK 
National Institute for Health and Care Excellence (NICE) guidelines,32 which either give 
guidance based on expert consensus without underpinning evidence, or note that it is not 
currently possible to make an evidence-based recommendation regarding correction of mild 
to moderate metabolic acidosis in CKD. Clinical practice varies in the use of bicarbonate 
therapy for patients with CKD . Measurement and correction of acidosis is often part of 
standard care for patients managed under renal services, but is less common for patients 
managed by primary care or geriatric medicine services.   
 
Imperative for the current trial 
Few trials to date have included many older people with CKD, despite older people being the 
group most likely to have CKD. CKD in older patients is almost always accompanied by 
multimorbidity, and thus a narrow focus on measures of kidney disease alone is unlikely to 
reflect what is important to the patient. Any trial seeking to provide a comprehensive view of 
the net health gain or loss from treatment in older patients with CKD must therefore measure 
a range of outcomes of relevance to older people, and must seek evidence of both benefit and 
harm – an approach that is more likely to provide appropriate evidence on which to base 
guidelines,.  
 
Chronic kidney disease is common, and affects many older people. The accompanying 
acidosis may worsen the muscle weakness that affects many older people as discussed above; 
muscle weakness is a key risk factor for falls, disability, institutionalisation and premature 
death.33 Only a minority of older people with CKD progress to a point where they require 
dialysis for renal failure. However, the effect on quality of life, and the cost burden from 
dialysis are considerable; between £20000 and £25000 per patient per year, depending on 
modality and setting of dialysis.34 Finally, cardiovascular disease is the leading cause of 
hospitalization and death in older people, and is responsible itself for one half to one third of 
the decline in physical function seen with age.  
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Thus an intervention that successfully reverses acidosis in this older population may be able 
to simultaneously improve multiple important, associated comorbidities in older people, with 
consequent improvements in function and quality of life, as well as potential reductions in 
hospitalization and later institutionalization. 
 
Trial objectives* 
The primary objective of the BiCARB trial was to determine whether oral bicarbonate 
therapy improves physical function compared to placebo in older people with CKD and mild 
acidosis. The secondary objectives were a) to determine whether oral bicarbonate therapy 
improves health-related quality of life compared to placebo; b) to compare the impact of oral 
bicarbonate therapy against placebo on biochemical markers of chronic kidney disease; c) to 
assess whether use of oral bicarbonate therapy is associated with an excess of adverse events 
compared with placebo; d) to estimate the cost-effectiveness of using oral bicarbonate 
therapy compared with placebo; and e) to assess the effect of oral bicarbonate therapy 
compared with placebo on bone turnover and vascular health as assessed by biochemical 
markers. 
 
 
 
 
*Previously published by the authors in https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-015-
0843-6. Reused under CC-BY licence - http://creativecommons.org/licenses/by/4.0 
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Chapter 2. Trial Design 
The trial was a randomised, double-blind, parallel group, placebo-controlled trial, analysed 
by intention to treat. The treatment and follow up were planned to last up to two years for 
each participant. 
 
Participants 
 
Target population for the trial 
The original commissioning brief for the trial stipulated a target population of older patients 
with advanced chronic kidney disease (stage 4 or 5, not on dialysis) and mild acidosis 
(bicarbonate concentration of <22 mmol/L); our inclusion and exclusion criteria reflected 
these points. 
 
Inclusion and exclusion criteria 
Participants were recruited from primary and secondary care, including nephrology, geriatric 
medicine and general medicine clinics according to the following inclusion and exclusion 
criteria: 
 
Inclusion criteria: 
• Willing and able to give informed consent for participation in the study 
• Male or female aged 60 years or above 
• Last known estimated Glomerular Filtration Rate (eGFR) <30 mL/min/1.73 m2 by 
MDRD4 equation35  
• Serum bicarbonate <22 mmol/L 
• Able (in the investigator’s opinion) and willing to comply with all study requirements. 
 
Exclusion criteria: 
• Severe cognitive impairment precluding written informed consent 
• Already taking bicarbonate therapy unless a three month washout period is planned 
• Documented renal tubular acidosis 
• On renal replacement therapy (haemodialysis or peritoneal dialysis) 
• Anticipated to start renal replacement therapy within three months 
• Terminally ill, as defined as less than three months expected survival 
29 
 
• Decompensated chronic heart failure 
• Bisphosphonate therapy 
• Uncontrolled hypertension at screening visit (BP>150/90 mmHg despite use of four 
agents), unless evidence available from home or 24 hour blood pressure monitoring 
that blood pressure is usually controlled. 
• Participation in another clinical trial (not including observational studies and 
registries) concurrently or within 30 days prior to screening for entry into this trial 
• Known allergy to sodium bicarbonate tablets or lactose 
 
Trial intervention and comparator 
The trial intervention was oral sodium bicarbonate tablets. Each tablet contained 500 mg 
sodium bicarbonate or matching placebo tablets (equivalent to six mmol of sodium and six 
mmol of bicarbonate). The initial dose dispensed was one tablet three times a day. If 
bicarbonate levels were still below 22 mmol/L at three months, the dose was increased to two 
tablets three times a day for the remaining duration of participation. No specific measures 
were used to enhance adherence beyond reminding participants to take medication at each 
study contact. 
 
Outcome measures 
Primary outcome 
The primary outcome for the trial was the Short Physical Performance Battery (SPPB) score 
at 12 months, adjusted for baseline values. The SPPB is a test of lower limb strength and 
balance.36 It comprises three tests – a balance test (tandem balance, semi-tandem balance and 
single leg balance), a timed sit to stand from a chair five times, and gait speed over a four 
metre course. The test is scored from zero (worst; includes those who cannot perform any 
component) to 12 (best score). The SPPB is a robust predictor of a range of adverse outcomes 
in older people including death, dependency and future disability.37,38 
 
Secondary outcomes 
Table 1 lists the secondary outcomes measured in the trial and their timepoints, encompassing 
a range of measures of physical function, anthropometry, quality of life, vascular health and 
bone health. For all secondary outcomes, data from all available timepoints were used in 
repeated-measures analyses. Repeated-measures evaluation of the SPPB (in contrast with the 
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12 month primary outcome measure) was therefore a secondary outcome, along with the 
outcomes listed in Table 1. Details of methods for outcomes measurement and analysis are 
given in Appendix 3. 
 
Table 1. List of secondary outcomes in the BiCARB trial 
Test Timepoints measured 
Physical function and anthropometry  
Six minute walk distance39 0,3,6,12,24 months 
Handgrip strength40 0,3,6,12,24 months 
Weight 0,3,6,12,24 months 
Mid-arm muscle circumference41 0,3,6,12,24 months 
Triceps skinfold thickness41 0,3,6,12,24 months 
Mid-thigh circumference41 0,3,6,12,24 months 
Health-related quality of life  
EQ-5D-3L score42 0,3,6,12,24 months 
EQ-5D thermometer42 0,3,6,12,24 months 
KDQoL questionnaire43 0,3,6,12,24 months 
ICECAP questionnaire44 0,3,6,12,24 months 
Renal function  
Creatinine and estimated glomerular filtration rate 0,3,6,12,24 months 
Cystatin C 0,3,6,12,24 months 
Urinary albumin/creatinine ratio 0,3,6,12,24 months 
Bone and mineral metabolism  
Tartrate-resistant acid phosphatase (TRACP)-5b 0, 12,24 months 
Bone-specific alkaline phosphatase 0, 12,24 months 
Parathyroid hormone 0, 12,24 months 
25-hydroxyvitamin D and 1,25 hydroxyvitamin D 0, 12,24 months 
Serum calcium and serum phosphate 0,3,6,12,24 months 
Vascular risk markers  
NT-pro-B-type natriuretic peptide 0, 12,24 months 
Systolic and diastolic blood pressure 0,3,6,12,24 months 
Total cholesterol 0,3,6,12,24 months 
Other biochemistry  
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Thyroid stimulating hormone 0,3,6,12,24 months 
Serum potassium, serum albumin, serum bicarbonate 0,3,6,12,24 months 
Haemoglobin 0,3,6,12,24 months 
Glycosylated haemoglobin (HbA1c) 0,3,6,12,24 months 
EQ5D: EuroQoL 5 dimension questionnaire. KDQoL: Kidney Disease Quality of Life questionnaire. ICECAP: Investigating 
Choice Experiments for the preferences of older people CAPability tool 
 
Health economic outcomes 
Data on primary care and secondary care (inpatient and outpatient) use were captured by 
questionnaire at each study visit to inform the health economic analysis. Participants were 
asked to recall their frequency of service use over the previous month at each follow-up 
point.  Service use included hospital admissions, day case visits, outpatient clinic visit, day 
hospital visit, other health care professionals visit (general practitioner, district nurse visit, 
physiotherapist, occupational therapist, speech therapist visit) and other social care visit (day 
centre visit and home helper/carer). National published sources were used to value the 
resources used (see Appendix 5) at these time points, and the sum of these responses was 
used to calculate annual costs for the first and second year of follow-up. To assess outcomes, 
the EQ-5D-3L, ICECAP-O and global life satisfaction measures were used. 
 
Sample size calculation 
We based the original sample size calculation on the ability to detect a one point difference in 
the SPPB (i.e. the primary outcome). This difference has been proposed as the Minimum 
Clinically Important Difference (MCID) by previous investigators.45 Previous work with older 
people showed a standard deviation of 2.6 for the SPPB. To detect a one point difference 
between groups at 12 months given this standard deviation would require 143 participants per 
group given a two-sided alpha = 0.05 and power = 90% 
 
To ensure that the trial had sufficient power for the key secondary outcome of health-related 
quality of life, we also estimated the sample size required to detect the MCID for the EQ-5D 
measure. For the EQ-5D the MCID is 0.074.46 To detect this with two-sided alpha = 0.05 and 
power of 90%, assuming a SD of change of 0.2 as found in our previous studies, would require 
154 patients per group.  
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Assuming a 10% loss to follow up every six months (based on previous medication trials in 
frail older people),47,48 we estimated that we would require 380 patients (190 per group) to 
ensure adequate power for the primary outcome and the EQ-5D at 12 months. 
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Chapter 3. Methods 
 
Regulatory approvals 
The BiCARB trial was a Clinical Trial of an Investigational Medicinal Product (CTIMP). As 
such, the trial was subject to approval and oversight from the Medicines and Healthcare 
Regulatory Authority (EudraCT number 2011-005271-16; Clinical Trial Authorisation 
number 41692/0001/001-0001). Ethics approval was granted by the East of Scotland NHS 
research ethics committee (approval 12/ES/0023). The trial was co-sponsored by the 
University of Dundee and NHS Tayside (Tayside Academic Health Sciences Collaboration). 
The trial was registered at www.isrctn.com, with the identifier ISRCTN09486651. 
 
Participants 
 
Site participation 
At the trial planning stage, a core of six sites were selected (Dundee, Aberdeen, Salford, 
Sheffield, Canterbury and Guys/St Thomas’s). Early in the course of the trial, the decision 
was taken to recruit from a much larger number of sites to address issues of slow recruitment 
rates; potential sites were approached via the NIHR Renal Clinical Research Network. Sites 
were selected on the basis of willingness to participate, access to a local investigator with 
appropriate Good Clinical Practice (GCP) training, and sufficient nephrology colleagues with 
clinical equipoise on the trial intervention at the site to support randomising participants 
rather than immediately commencing oral bicarbonate therapy. 
 
Participant identification 
Participants were identified via secondary care services, either by screening attendees at 
clinics (predominantly renal clinics including low-clearance clinics), or by searching local 
renal and biochemistry databases. At two sites (Dundee and Aberdeen), participants were also 
sought via searches of primary care records. Initial searches focussed on identifying patients 
with CKD category 4 or 5, not on dialysis, and with historical serum bicarbonate 
concentrations of <22 mmol/L. 
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Recruitment process 
Potentially eligible participants were given study information and invited to attend a 
screening visit. After obtaining written informed consent, medical history and medication use 
were recorded to check for exclusion criteria. If creatinine and bicarbonate results were 
available within the previous month, these values were used to determine eligibility. If these 
results were not available, a screening blood sample was taken to measure creatinine 
concentration, derive eGFR (by MDRD4 equation) and measure serum bicarbonate 
concentration. 
 
Participants found to be eligible at the screening visit either underwent the baseline study 
assessments on the same day (if historical blood results were available) or at a separate visit 
(if screening bloods were used). 
 
Washout arrangements 
For potentially eligible participants already taking oral sodium bicarbonate who wished to 
participate, consent was obtained and a three-month washout period instituted. After the 
washout period, the screening visit was performed and only those participants fulfilling 
eligibility criteria at the screening visit proceeded to baseline assessment and randomisation. 
 
Randomisation and treatment allocation 
Randomisation was performed using an interactive web-based randomisation, drug 
assignment and inventory management system (TRuST) run by the Health Informatics 
Centre, University of Dundee. The system was run independently from the research team to 
preserve allocation concealment. Randomisation was performed in a one to one ratio, 
stratified by site, and employed a minimisation algorithm to balance male vs female sex, 
CKD category 4 vs stage 5, and age <75 years versus >=75 years.  
 
Participants were allocated study medication bottles (one bottle per month) with either 500mg 
sodium bicarbonate tablets or matching placebo tablets; bottles were allocated based on bottle 
ID numbers generated by the TRuST randomisation system. 
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Unmasking 
The treatment code was broken only when the clinical team treating the participant deemed 
knowledge of treatment allocation to be essential for management of the participant. 
Unmasking was performed by the clinical trials pharmacist at Dundee using the web-based 
randomisation and medication management system for the trial. The pharmacist was 
contactable via a 24 hour hotline. After unmasking, the TRuST system automatically 
informed the trial team of the unmasking event without disclosing treatment allocation. No 
tests for the success of masking (for example asking trial personnel to guess which group 
participants were allocated to) were performed. 
 
Intervention and comparator 
The trial intervention consisted of either 500 mg sodium bicarbonate or matching placebo 
tablets (containing lactose and microcrystalline cellulose). Active and placebo tablets were 
manufactured and bottled by Legosan AB (Kumla, Sweden). Bottles were imported to the 
UK via Tayside Pharmaceuticals, Dundee, UK, who undertook quality testing, Qualified 
Person (QP) release, and distributed bottles to participating sites. Study medications were 
held at site pharmacies under temperature controlled conditions prior to dispensing to 
participants. For the first three months of participation, participants were instructed to take 
one tablet three times per day. 
 
Uptitration 
Uptitration took place in a double-dummy fashion. Bicarbonate concentrations were 
measured at the three month visit. If bicarbonate concentrations were <22 mmol/L, 
participants were instructed to increase their intake of study medication to two tablets three 
times a day. If bicarbonate concentrations were >=22 mmol/L, participants were instructed to 
continue taking one tablet three times a day for the remainder of their time in the trial. 
 
Returned medication and tablet counting 
At each visit, unused tablets were returned by participants, counted, and entered into the 
study database to allow adherence to be calculated. 
 
Outcomes measurement 
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Outcomes were measured at baseline, three, six, 12 and 24 months. Outcomes were collected 
by research nurses at each site who were masked to treatment allocation. Figure 1 shows the 
study processes at each visit from screening to the end of trial participation. 
 
Figure 1. Flow of participant visits and activities through trial 
 
AE: Adverse event. BMI: Body mass index. BP: Blood pressure. Con Meds: Concomitant medications. eGFR: estimated 
Glomerular Filtration Rate. EQ5D: EuroQoL 5 dimension quality of life tool. IMP: Investigational Medicinal Product. 
KDQoL: Kidney Disease Quality of Life tool. SPPB: Short Physical Performance Battery 
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Data management 
Trial data were collected onto paper case report forms, then entered onto a trial-specific 
database built using OpenClinica software. Participants were identified using a unique study 
identifier, and data were stored on a secure, backed-up University of Dundee server system. 
Source data verification was conducted for all randomised participants for age, sex, inclusion 
and exclusion criteria, laboratory values analysed as part of routine clinical practice, baseline 
medications, and adverse events. Batch validation and database audit procedures were run as 
outlined in the trial Data Management Plan. Target error rates for the primary outcome and 
adverse events were set at <0.5%, and for other audited fields at <2% with corrections made 
until error rates fell within these limits. 
 
Safety reporting 
All adverse events (serious and non-serious) were collected at each site on adverse event 
logs. Adverse events were coded centrally by System Organ Class and Preferred Term using 
the Medical Dictionary for Regulatory Activities (MedDRA) coding dictionary version 16.1 
(www.meddra.org). Given the anticipated high frequency of adverse events in this study 
population, Serious Adverse Events (SAE) were collected, but not reported to the trial 
sponsor or to the regulatory authority (MHRA) if they fell into the following categories: 
 
- Any new cardiovascular event 
- Any new diagnosis or treatment of cancer 
- Any death or hospitalisation due to fall or fracture 
- Any death or hospitalisation due to infection 
- Any death or hospitalisation due to exacerbation of an existing medical condition. 
- Any admission for elective or planned investigation or treatment 
- Death, admission or treatment for deteriorating renal function, high or low potassium 
concentrations 
 
All adverse events (including those in the above list) were presented to the independent Data 
Monitoring Committee classified by MedDRA System Organ Class; prespecified outcomes 
of particular interest (death, worsening heart failure, fluid overload or breathlessness) were 
also presented. All adverse events were included in the analysis reported here. 
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Trial Oversight Committees 
An independent Data Monitoring Committee (DMC) met every six months. The DMC 
comprised an experienced trials biostatistician, an academic geriatrician and an academic 
nephrologist. The DMC had access to unblinded data on baseline participant characteristics 
and adverse events. The DMC reported to the chair of the independent Trial Steering 
Committee, were appointed by NIHR, and operated under an agreed charter. 
 
The independent Trial Steering Committee (TSC) was appointed by NIHR, and was chaired 
by an experienced trialist specialising in geriatric medicine. Other independent members of 
the TSC were an academic nephrologist, an academic geriatrician, and a lay member with 
personal experience of kidney disease. The TSC met at least every six months over the course 
of the trial; additional meetings were held as required for timely decision making. The TSC 
chair reported to the project manager at NIHR by letter and minutes after each TSC meeting; 
the TSC operated under an agreed Charter. 
 
Day to day management of the trial was performed by the Trial Management Group (TMG) 
comprising the lead applicant, co-applicants, and Tayside Clinical Trials Unit (CTU) staff. 
Local investigators and research nurses at each site were invited to join all TMG meetings, 
which took place monthly until the end of recruitment, then every two months until the end of 
the grant funding period. Monthly teleconferences between the trial manager and research 
nurses were used to share best recruitment practice and to troubleshoot trial processes. 
 
Patient and public involvement 
A patient representative formed part of the independent TSC and had input into the conduct 
of the trial including significant changes to the protocol; this representative also reviewed the 
final results. The study design and outcome measures were discussed with a panel of older 
people at the design stage of the trial who provided advice and feedback. 
 
Important changes to the trial design and conduct after trial commencement 
Several significant changes were made to the conduct of the trial after commencement, 
mostly in response to slow recruitment: 
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- The number of sites planned was originally 6; this was expanded to the final 27 to 
address slow recruitment 
- A substudy at two sites (Dundee and Aberdeen) was originally planned to examine 
bone mineral density by dual energy x-ray absorptiometry (DEXA) and vascular 
stiffness by applanation tonometry. These substudies were discontinued due to poor 
recruitment with only two participants undergoing the substudy measurements. 
- The exclusion criteria were relaxed early in the recruitment phase following a review 
of reasons for non-recruitment. Changes were made to reduce the lower age limit 
from 65 to 60; to allow inclusion of those on calcium acetate or sevelamer, and those 
with hypertension controlled on home monitoring despite high office blood pressure 
readings. Both these phosphate binders are routinely used alongside bicarbonate in 
clinical practice, and home monitoring of blood pressure is increasingly used in 
determining the adequacy of blood pressure control in clinical practice. These changes 
were therefore deemed not to compromise the safety or scientific integrity of the trial, 
but were likely to enhance the generalisability of the results by expanding the pool of 
eligible participants. In addition provision was made for including patients currently 
taking sodium bicarbonate if they underwent a 3 month washout period. 
- The TSC took the decision in conjunction with the funder to stop recruitment once 
300 of the original target of 380 participants had been randomised. This decision was 
taken in view of slowing recruitment rates; the sample size calculations were revisited 
prior to this decision being taken, as discussed under ‘Sample size’ below 
- The TSC took the decision in conjunction with the funder to truncate follow up once 
all participants had reached the primary outcome point of 12 months. The decision 
was taken to enable a prompt conclusion to the trial so that results could be 
disseminated in a timely fashion. The decision was not based on an interim analysis of 
the results. A small number of individuals did not therefore progress to the 24 month 
follow up point. 
- Two extensions to the recruitment time were granted by NIHR to compensate for 
slower than anticipated recruitment. 
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Re-estimation of sample size 
To inform the decision on whether to terminate recruitment once 300 participants had been 
randomised, a revised sample size calculation was prepared by the research team and was 
considered by the TSC. This calculation was done without knowledge of treatment allocation 
or of any follow up data beyond baseline values and standard deviations for the trial 
population. 
 
The revised sample size calculation assumed the use of a mixed-model repeated measures 
analysis with two time points (12 month follow up and baseline), a standard deviation of 2.6 
for the primary outcome of the SPPB, an attrition rate of 30% by 12 months, and an alpha 
level of 0.05. Assuming a within-person correlation of 0.7, 300 participants would give 85% 
power to detect a one point difference in the SPPB between groups (the minimum clinically 
important difference) at 12 months. Assuming a within-person correlation of 0.6, the same 
sample size would give 87% power to detect this difference. 
 
Based on these revised power estimates, the TSC recommended that recruitment stop at 300 
participants, as sufficient power to detect the MCID for the primary outcome would still be 
present, and continuing recruitment would risk greatly prolonging the trial to little benefit in 
terms of statistical power. 
 
Statistical analysis 
A prespecified Statistical Analysis Plan (SAP) was drafted, reviewed by the TMG and the 
independent TSC, and signed off before the last visit of the last participant. The full SAP can 
be accessed via the project webpage [link]. 
 
The primary outcome (between group difference in the SPPB at 12 months) was analysed 
using linear mixed models, adjusted for baseline measurements, minimisation variables (age, 
sex, and stage of CKD), and a random effect variable for recruitment site. Prespecified 
subgroup analyses for the primary outcome were conducted (SPPB >=10 vs <10, CKD 
category 4 vs stage 5, age <75 vs >=75 years, male vs female, baseline bicarbonate <18 
mmol/L vs >=18 mmol/L). These factors were selected as being both of clinical interest and 
likely to be related to the primary outcome based on previous work. Sensitivity analyses were 
planned for >80% vs <=80% adherence, exclusion of those undergoing washout prior to 
41 
 
randomisation, and using multiple imputation for missing data. Multiple imputation was 
performed with SAS proc MI, using a Markov Chain Monte Carlo method with multiple 
chains over 1000 iterations. Predictor variables were visit, sex, age group, CKD stage and 
practice. 
 
Secondary outcomes were analysed using repeated measures models, adjusted for baseline 
values and minimisation variables as above. Time-to-event analyses (time to death, time to 
commencing renal replacement therapy) were conducted using Cox proportional hazards 
models adjusted for minimisation variables as above. For all analyses, a two-sided p value of 
<0.05 was taken as significant with no adjustment for multiple testing. Analyses were 
performed using Statistical Analysis System (SAS) v9.4 software (SAS Institute Inc, Cary, 
NC, USA). Unmasking of randomisation groups was performed only after completing the 
statistical analysis. 
 
Health Economic analysis 
A prespecified Health Economic Analysis Plan (HEAP) was also drafted, reviewed by the 
TMG and signed off before the last visit of the last participant. The HEAP is can be accessed 
via the project webpage [link]. 
 
The primary aim was to assess the cost effectiveness of the addition of bicarbonate therapy, 
relative to placebo, from the perspective of the UK health and social care system. A cost-
utility analysis was undertaken which involved estimation of the incremental costs and 
incremental effects (effectiveness was measured using Quality Adjusted Life Years, QALYs, 
based on responses to the EQ-5D-3L instrument).  Estimation was performed using 
generalised linear regression modelling, with adjustment for skewed data and for baseline 
differences in cost, EQ-5D-3L and other patient characteristics (age, gender, stage of CKD).  
Non-parametric bootstrap methods49 were used for calculating confidence intervals around 
cost and QALY differences.  Cost effectiveness acceptability curves were employed to show 
the probability that bicarbonate therapy was cost effective for different values of willingness 
to pay per additional QALY.50 
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Chapter 4. Clinical Effectiveness results 
 
Recruitment 
 
A total of 300 participants were randomised into the trial between May 2013 and February 
2017. Appendix 4 shows cumulative recruitment per month throughout the trial recruitment 
phase (Appendix 4 Figures 1 and 2), and recruitment broken down by site (Appendix 
4 Table 1). Following discussion between the trial team, the independent DMC and TSC 
and the funder, recruitment was terminated at this point due to very low ongoing recruitment 
rates. As part of this decision-making process, revised sample size / power calculations 
indicated that under the proposed analysis method for the primary outcome, the trial had 87% 
power to detect the minimum clinically important difference with the recruited sample size.  
 
Flow of participants through the trial 
Figure 2 shows the flow of participants through the trial, using the format recommended by 
the Consolidated Standards of Reporting of Trials (CONSORT).50 Dropout rates were similar 
in both arms at each timepoint, but overall dropout rates were slightly higher than anticipated 
(18% at 6 months and 27% at 12 months). Once all participants had completed their 12 
month (primary outcome) visit, the TSC recommended that further follow up for the last 40 
participants be truncated; the last patient visit occurred in February 2018. These participants 
did not therefore progress to their 18 month or 24 month visits, and thus dropout after 12 
months appears artefactually higher. Only four participants underwent the three-month 
washout option prior to the screening visit. 
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Figure 2. CONSORT diagram 
 
 
(*some did not attend visit but had not dropped out) 
W = withdrawn by investigator. P = participant chose with withdraw. A = withdrew due to adverse event. D = Died. L = lost 
to follow up. C = early study completion due to truncated follow up. O = other. 
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Participant baseline characteristics 
Participant baseline characteristics are presented in Table 2. The two groups were well 
balanced for most key baseline characteristics, including aetiology of renal dysfunction. 
 
Table 2. Baseline characteristics of randomised participants (n=300) 
 Sodium 
bicarbonate 
(n=152) 
Placebo 
(n=148) 
Mean age (years) (SD) 73.9 (7.6) 74.0 (6.6) 
Age 60-69 (%) 57 (37.5) 35 (23.6) 
Age 70-79 (%) 53 (34.9) 81 (54.7) 
Age 80 and over (%) 42 (27.6) 32 (21.6) 
Female sex (%) 42 (27.6) 44 (29.7) 
Ethnicity White 144 (94.7) 143 (96.6) 
East Asian 0 (0) 1 (0.7) 
Black 1 (0.7) 0 (0) 
South Asian 4 (2.6) 2 (1.4) 
Hispanic 1 (0.7) 0 (0) 
Other 2 (1.3) 2 (1.4) 
Cause of renal 
dysfunction 
Hypertension 37 (24.3) 40 (27.0) 
Diabetes mellitus 23 (15.1) 23 (15.5) 
Glomerulonephritis 9 (5.9) 11 (7.4) 
Polycystic kidney disease 11 (7.2) 9 (6.1) 
Vascular disease 19 (12.5) 21 (14.2) 
Other 52 (34.2) 63 (42.6) 
Not known 31 (20.4) 22 (14.9) 
Cardiovascular 
comorbidity 
Hypertension 135 (88.8) 129 (87.2) 
Diabetes mellitus 54 (35.5) 47 (31.8) 
Ischaemic heart disease 26 (17.1) 31 (20.9) 
Stroke 16 (10.5) 12 (8.1) 
Heart failure 19 (12.5) 5 (3.4) 
Peripheral vascular disease 14 (9.2) 10 (6.8) 
Previous fragility fracture (%) 2 (1.3) 5 (3.4) 
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Mean number of medications (SD) 8.2 (3.7) 7.9 (3.3) 
Medication use:  ACEi/ARB 105 (69.1) 91 (61.5) 
 Phosphate binder 32 (21.1) 28 (18.9) 
 Activated vitamin D 77 (50.7) 73 (49.3) 
 Erythropoietin 89 (58.6) 106 (71.6) 
 Iron 60 (39.5) 51 (34.5) 
Mean eGFR (mL/min/1.73m2) (SD) 19.7 (6.5) 18.2 (6.4) 
CKD category 5 (%) 72 (47.4) 69 (46.6) 
Mean serum bicarbonate (mmol/L) (SD) 20.6 (2.6) 20.1 (2.5) 
Mean haemoglobin (g/L) (SD) 115 (14) 117 (17) 
Mean serum potassium (mmol/L) (SD) 4.9 (0.5) 4.9 (0.5) 
Mean Short physical performance battery (SD) 8.0 (2.4) 8.1 (2.2) 
Mean six-minute walk distance (m) (SD) 304 (134) 317 (133) 
Mean handgrip 
strength (kg) (SD) 
Males 26.6 (8.8) 28.0 (7.6) 
Females 15.4 (4.8) 15.8 (4.4) 
Mean body mass index (kg/m2) (SD) 28.9 (4.5) 28.3 (4.6) 
Mean mid-arm muscle circumference (cm) (SD) 24.9 (3.6) 24.8 (4.0) 
Mean triceps skinfold thickness (mm) (SD) 16 (8) 17 (9) 
Mean mid-thigh circumference (cm) (SD) 47.4 (7.0) 46.8 (7.0) 
Mean EQ-5D-3L (SD) 0.73 (0.22) 0.74 (0.24) 
Mean EQ-5D thermometer (SD) 69 (19) 71 (19) 
Mean KDQoL scores SF36 PCS (SD) 36 (11) 36 (11) 
SF36 MCS (SD) 53 (11) 534 (9) 
Burden (SD) 75 (26) 75 (25) 
Symptoms (SD) 79 (14) 81 (12) 
Effects (SD) 86 (14) 87 (15) 
Mean office systolic blood pressure (mmHg) (SD) 143 (18) 143 (18) 
Mean office diastolic blood pressure (mmHg) (SD) 75 (11) 73 (10) 
ACEi: Angiotensin converting enzyme inhibitor. ARB: Angiotensin receptor blocker. CKD: Chronic kidney disease. 
KDQOL: Kidney disease quality of life questionnaire. SF-36: Short-form 36 item questionnaire. PCS: Physical component 
summary. MCS: Mental component summary. EQ-5D: EuroQoL 5 dimension quality of life questionnaire  
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Adherence and effect of intervention on serum bicarbonate 
Data on adherence to study medication are shown in Table 3. Adherence was moderate, with 
approximately 50% in both arms exceeding the commonly-used threshold of 80% used to 
denote good adherence. The mean prescribed dose of bicarbonate in the bicarbonate arm 
across the whole follow up period was 1.88 grams per day (compared to a maximum possible 
dose of 3 grams per day), and the mean ingested dose of bicarbonate in the bicarbonate arm 
across the whole follow up period was 1.39 grams per day. 
 
Table 3. Intervention uptitration and adherence 
Visit  Bicarbonate group Placebo group 
3 months 500mg 3x/day (%) 82 (53.9) 45 (30.4) 
 1000mg 3x/day (%) 46 (30.3) 83 (56.1) 
 Not dispensed (%) 12 (7.9) 6 (4.1) 
 Dropped out before 3 month visit (%) 12 (7.9) 8 (5.4) 
% Adherence (SD) 72.8 (35.2) 73.4 (39.6) 
Adherence <=80% (%) 76 (50.0) 73 (49.3) 
 
A modest but significant increase in serum bicarbonate concentration was seen in the 
intervention arm by 3 months; this difference attenuated with time and was no longer 
significant by 24 months, as shown in Figure 3. The treatment effect of bicarbonate 
supplementation across the whole follow up period was 1.1 mmol/L (95% CI 0.6 to 1.6, 
p<0.001); bicarbonate levels at each follow up time point are included later in the report in 
Table 7. 
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Figure 3: Change in bicarbonate concentration relative to baseline 
 
 
Primary outcome 
Table 4 shows the primary outcome analysis - the difference in SPPB at 12 months between 
groups. No significant effect of bicarbonate treatment was seen on the primary outcome 
(treatment effect -0.4 points, 95% CI -0.9 to 0.1, p=0.15); analysis adjusted only for baseline 
SPPB and analyses adjusted for baseline SPPB, age, sex and CKD category gave the same 
result. Multiple imputation to account for missing data gave similar results (treatment effect -
0.3 points, 95% CI -1.0 to 0.3, p=0.29). As only four participants underwent the washout 
period prior to randomisation, the sensitivity analysis excluding this subgroup was not 
conducted. 
 
 
 
 
48 
 
Table 4. Primary outcome (Short physical performance battery at 12 months) 
 Bicarbonate 
group 
Placebo group Adjusted treatment 
effect* (95% CI) 
p 
Baseline SPPB (SD) 8.0 (2.4) 
(n=140) 
8.1 (2.2) 
(n=134) 
-0.4 (-0.9 to 0.1) 0.15 
12 month SPPB (SD) 8.3 (2.5) 
(n=97) 
8.8 (2.2) 
(n=90) 
*adjusted for baseline SPPB, age, sex and CKD category (4 vs 5). SPPB: Short Physical Performance Battery. N= 
 
Subgroup analyses 
No significant interaction was seen on subgroup analyses (age, sex, CKD category, high vs 
low baseline bicarbonate concentration, high vs low baseline SPPB), with all subgroups 
showing similar effect sizes for the primary outcome; all tests for interaction were non-
significant. Details are presented in Figure 4.  
 
Figure 4. Subgroup analyses for primary outcome 
 
 
Effect of adherence on primary outcome 
A further pre-planned subgroup analysis was conducted, comparing the primary outcome 
treatment effect for those with good adherence (defined a priori as >80%) versus poorer 
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adherence (defined a priori as <=80%).  Those with good adherence showed an adjusted 
treatment effect at 12 months of -0.6 (95% CI -1.4 to 0.1; p=0.07), compared to an adjusted 
treatment effect of 0.0 (95% CI -0.7 to 0.7; p=0.97) for those with poorer adherence. The 
difference in treatment effects was not significant (p for interaction = 0.27)  
 
Secondary outcomes 
 
Physical function 
Repeated measures analysis showed that SPPB was slightly worse in the bicarbonate arm 
compared to placebo. Similarly, six minute walk distance and grip strength showed an 
adverse treatment effect on repeated measures analyses. Details are presented in Table 5. 
 
Anthropometry 
No significant difference was seen on repeated measures analysis between groups for weight, 
triceps skinfold thickness, mid-thigh circumference or mid-arm muscle circumference. 
Details are presented in Table 5. 
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Table 5. Secondary outcomes – measures of physical function and anthropometry 
  Bicarbonate Placebo Treatment 
effect 
(95% CI) 
p 
SPPB 
(SD) 
Baseline 8.0 (2.4) n=140 8.1 (2.2) n=134 
-0.6  
(-1.0 to -0.1) 
0.02 
3 months 8.2 (2.2) n=120 8.7 (2.3) n=123 
6 months 8.2 (2.5) n=113 8.9 (2.6) n=111 
12 months 8.3 (2.5) n=97 8.8 (2.2) n=90 
24 months 7.7 (2.5) n=72 8.7 (2.5) n=73 
 
6 min 
walk 
(m) 
(SD) 
Baseline 304 (134) n=151 317 (133) n=148 
-33  
(-62 to -4) 
0.02 
3 months 308 (143) n=134 333 (131) n=128 
6 months 307 (151) n=127 334 (147) n=114 
12 months 294 (162) n=109 336 (154) n=101 
24 months 300 (167) n=80 327 (184) n=79 
 
  Men Women Men Women   
Grip 
strength 
(kg) 
(SD) 
Baseline 26.6 (8.8) n=110 15.4 (4.8) n=42 28.0 (7.6) n=104 15.8 (4.4) n=44 
-1.5  
(-2.8 to -0.2) 
0.03 
3 months 26.5 (7.1) n=103 15.8 (4.8) n=35 27.5 (7.9) n=95 16.3 (4.1) n=37 
6 months 26.3 (7.1) n=97 15.1 (4.7) n=31 28.3 (7.2) n=83 16.6 (4.9) n=33 
12 months 25.9 (7.2) n=85 15.2 (5.2) n=27 28.4 (7.9) n=72 15.5 (4.1) n=30 
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24 months 25.5 (8.3) n=57 14.1 (5.5) n=23 28.7 (7.3) n=56 15.1 (3.6) n=23 
 
Weight 
(kg) 
(SD) 
Baseline 82.3 (16.9) n=152 81.5 (15.9) n=148 
0.2  
(-2.9 to 3.4) 
0.89 
3 months 83.0 (16.7) n=137 82.2 (15.4) n=131 
6 months 83.1 (16.7) n=127 81.1 (14.5) n=117 
12 months 83.4 (16.3) n=112 81.1 (14.6) n=102 
24 months 80.1 (14.5) n=81 80.9 (14.6) n=79 
 
MAMC 
(cm) 
(SD) 
Baseline 24.9 (3.6) n=150 24.8 (4.0) n=147 
0.0  
(-0.6 to 0.6) 
0.99 
3 months 24.9 (3.5) n=136 25.2 (4.3) n=131 
6 months 25.1 (4.3) n=126 24.8 (4.1) n=115 
12 months 25.2 (3.2) n=112 24.4 (3.8) n=100 
24 months 24.2 (3.5) n=78 24.9 (3.2) n=77 
 
TSF 
(mm) 
(SD) 
Baseline 16 (8) n=151 17 (9) n=148 
-1  
(-2 to 1) 
0.34 
3 months 17 (9) n=138 17 (8) n=131 
6 months 15 (7) n=126 17 (9) n=116 
12 months 16 (10) n=111 17 (8) n=100 
24 months 15 (6) n=77 16 (8) n=79 
 
Baseline 47.4 (7.0) n=146 46.8 (7.0) n=143 0.1  0.80 
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MTC 
(cm) 
(SD) 
3 months 46.7 (6.7) n=133 46.7 (6.9) n=129 (-0.8 to 1.1) 
6 months 46.8 (5.4) n=128 48.3 (13.4) n=112 
12 months 46.5 (6.2) n=108 45.7 (6.7) n=99 
24 months 46.5 (5.2) n=79 46.4 (4.7) n=78 
Repeated measures ANOVA adjusted for baseline values, age, sex and CKD category 
SPPB: Short physical performance battery. MAMC: Mid arm muscle circumference. TSF: Triceps skinfold thickness. MTC: Mid-thigh circumference 
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Quality of life 
Both the health state and thermometer scores from the EQ-5D general health related quality 
of life tool showed an adverse effect of treatment on repeated measures analysis, but this did 
not reach statistical significance. Disease-specific quality of life domains from the KDQoL 
questionnaire showed no significant difference between groups, but the mental health 
component summary of the SF-36 health status questionnaire (part of the KDQoL 
questionnaire) was significantly worse in the bicarbonate arm compared to placebo. Details 
are presented in Table 6. 
 
Table 6. Secondary outcomes - Measures of quality of life 
  Bicarbonate Placebo Treatment 
effect 
(95%CI) 
p 
EQ-5D-3L Baseline 0.728 (0.220) n=143 0.739 (0.240) n=137 
-0.039 
(-0.079 to 
0.001) 
0.06 
3 months 0.706 (0.220) n=132 0.759 (0.212) n=123 
6 months 0.707 (0.209) n=120 0.768 (0.172) n=108 
12 months 0.699 (0.231) n=105 0.774 (0.165) n=94 
24 months 0.715 (0.243) n=70 0.751 (0.188) n=71 
 
EQ-5D 
thermometer 
Baseline 69 (19) n=146 71 (19) n=137 
-3 (-7 to 1) 0.09 
3 months 68 (19) n=134 70 (18) n=122 
6 months 67 (20) n=116 73 (16) n=110 
12 months 67 (19) n=106 71 (17) n=91 
24 months 68 (20) n=73 70 (18) n=72 
 
KDQOL 
Symptoms 
Baseline 79 (14) n=148 81 (12) n=141 
-1 (-3 to 2) 0.67 
3 months 80 (15) n=134 80 (15) n=128 
6 months 81 (13) n=122 80 (14) n=112 
12 months 78 (15) n=107 81 (14) n=96 
24 months 80 (14) n=76 81 (13) n=75 
 
Baseline 75 (25) n=148 75 (25) n=140 
-3 (-8 to 2) 0.20 
3 months 72 (27) n=133 77 (23) n=127 
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KDQOL 
Burden of 
disease 
6 months 74 (27) n=121 76 (23) n=112 
12 months 72 (27) n=107 75 (24) n=97 
24 months 72 (26) n=74 71 (27) n=74 
 
KDQOL 
Effect of 
disease 
Baseline 86 (14) n=146 87 (15) n=141 
-2 (-5 to 1) 0.25 
3 months 84 (17) n=133 86 (16) n=127 
6 months 85 (15) n=122 86 (15) n=113 
12 months 83 (18) n=106 86 (16) n=97 
24 months 84 (16) n=74 85 (19) n=74 
 
SF-36 PCS Baseline 36 (11) n=137 36 (11) n=133 
-1 (-4 to 1) 0.23 
3 months 34 (11) n=127 37 (11) n=115 
6 months 35 (11) n=115 37 (11) n=106 
12 months 35 (12) n=102 37 (10) n=87 
24 months 34 (11) n=70 36 (12) n=69 
 
SF-36 MCS Baseline 53 (11) n=137 54 (9) n=133 
-2 (-4 to 0) 0.03 
3 months 52 (10) n=127 54 (9) n=115 
6 months 52 (10) n=115 54 (10) n=106 
12 months 51 (10) n=102 53 (10) n=87 
24 months 51 (10) n=70 54 (11) n=69 
Repeated measures ANOVA adjusted for baseline values, age, sex and CKD category 
KDQOL: Kidney disease quality of life questionnaire. SF-36: Short-form 36 item questionnaire. PCS: Physical component 
summary. MCS: Mental component summary. EQ-5D: EuroQoL 5-dimension quality of life questionnaire 
 
Renal function 
No significant treatment effect was seen in renal function between the bicarbonate and 
placebo arms on repeated measures analysis; this was consistent whether using serum 
creatinine concentration, estimated GFR derived from serum creatinine, or using serum 
cystatin C concentration as an alternative marker of renal function. Urinary 
albumin/creatinine ratio showed no significant treatment effect between groups. Details are 
presented in Table 7. For those remaining under follow up in the trial, rates of decline in 
estimated GFR were low, as shown in Figure 5. 
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Table 7. Secondary outcomes - Measures of renal function and associated biochemistry 
  Bicarbonate Placebo Treatment 
effect* 
(95%CI) 
p 
Bicarbonate 
(mmol/L) 
Baseline 20.6 (2.6) n=152 20.1 (2.5) n=148 
1.1 
(0.6 to 1.6) 
<0.001 
3 months 22.4 (2.7) n=137 20.7 (3.4) n=133 
6 months 22.3 (2.7) n=124 21.1 (3.2) n=116 
12 months 22.5 (2.6) n=107 21.4 (3.9) n=98 
24 months 22.9 (4.1) n=79 22.5 (3.3) n=77 
 
eGFR 
(ml/min/ 
1.73m2) 
Baseline 19.7 (6.5) n=152 18.2 (6.4) n=148 
0.6** 
(-0.8 to 2.0) 
0.39 
3 months 18.8 (6.4) n=137 18.7 (7.6) n=133 
6 months 19.0 (7.3) n=126 18.6 (8.0) n=117 
12 months 17.9 (7.6) n=112 18.1 (7.7) n=101 
24 months 19.5 (10.2) n=79 18.0 (8.2) n=78 
 
Creatinine 
(umol/L) 
Baseline 289 (101) n=152 307 (103) n=148 
-8** 
(-28 to 13) 
0.46 
3 months 305 (118) n=137 309 (116) n=133 
6 months 311 (138) n=126 313 (120) n=117 
12 months 341 (177) n=112 320 (140) n=101 
24 months 319 (150) n=79 332 (150) n=78 
 
Cystatin C 
(mg/L) 
Baseline 3.11 (0.74) n=143 3.14 (0.74) n=136 
-0.01** 
(-0.17 to 
0.14) 
0.89 
3 months 3.20 (0.88) n=129 3.21 (0.85) n=120 
6 months 3.21 (0.87) n=121 3.21 (0.96) n=107 
12 months 3.41 (1.09) n=103 3.33 (1.04) n=93 
24 months 3.39 (1.20) n=71 3.35 (1.03) n=72 
 
Median  
urinary  
A/Cr ratio 
(IQR) 
Baseline 23 (7-79) n=142 22 (7-100) n=135 
0.32*** 
(-0.05 to 
0.70) 
0.09 
3 months 32 (8-112) n=131 26 (5-99) n=127 
6 months 25 (7-106) n=113 19 (7-76) n=110 
12 months 25 (7-115) n=102 21 (8-71) n=90 
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24 months 19 (6-91) n=63 21 (5-53) n=69 
Repeated measures ANOVA 
*adjusted for baseline values, age, sex and CKD category except for **adjusted for baseline values, age, sex 
***log-transformed value 
eGFR: estimated glomerular filtration rate by MDRD4 equation. A/Cr: Albumin/Creatinine 
 
 
 
 
 
Figure 5: Change in estimated glomerular filtration rate relative to baseline 
 
 
No difference was seen in the time to meeting criteria for a composite end point of decline in 
renal function, defined as the time to either doubling of baseline creatinine, 40% reduction in 
eGFR from baseline, or commencement of renal replacement therapy. The hazard ratio by 
Cox proportional hazards modelling, adjusted for age, sex and CKD category at baseline, for 
reaching this composite endpoint was 1.03 (95% CI 0.66 to 1.63); p=0.88. 
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Vascular health 
No significant treatment effect was found for blood pressure, total cholesterol or NT-pro-
BNP on repeated-measures analysis. Results are presented in Table 8, and the change in 
blood pressure relative to baseline in each group is shown in Figure 6. 
 
Table 8. Secondary outcomes - Markers of vascular health 
  Bicarbonate Placebo Treatment 
effect 
(95%CI)* 
p 
Median NT-
pro-BNP 
(pg/ml) 
(IQR) 
Baseline 5910  
(1678-
10221) 
n=115 4453  
(1555-
10521) 
n=115 
0.13 
(-0.18 to 
0.44)** 
0.42 
12 months 6809  
(1651-
12691) 
n=91 4158 
(1725-
9743) 
n=79 
24 months 5062 
(1748-
10357) 
n=80 5653 
(2369-
13287) 
n=72 
 
Total 
cholesterol 
(mmol/L) 
Baseline 4.3 (1.0) n=144 4.2 (1.1) n=141 
0.1 (-0.2 to 
0.3) 
0.58 
3 months 4.4 (1.1) n=135 4.2 (1.1) n=125 
6 months 4.4 (1.1) n=124 4.2 (1.1) n=113 
12 months 4.4 (1.2) n=104 4.3 (1.2) n=96 
24 months 4.4 (1.1) n=72 4.4 (1.2) n=77 
 
Systolic 
blood 
pressure 
(mmHg) 
Baseline 143 (18) n=152 143 (18) n=148 
0 (-4 to 3) 0.93 
3 months 143 (20) n=138 143 (19) n=133 
6 months 140 (20) n=128 141 (16) n=117 
12 months 143 (21) n=114 143 (16) n=103 
24 months 143 (21) n=81 142 (18) n=79 
 
Baseline 75 (11) n=152 73 (10) n=148 1 (-1 to 3) 0.16 
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Diastolic 
blood 
pressure 
(mmHg) 
3 months 75 (10) n=138 73 (11) n=133 
6 months 74 (12) n=128 73 (11) n=117 
12 months 74 (11) n=114 73 (9) n=103 
24 months 76 (11) n=81 72 (10) n=79 
Repeated measures ANOVA *adjusted for baseline values, minimisation variables, age, sex and CKD category ** log-
transformed values 
NT-pro-BNP: N-terminal pro B-type natriuretic peptide. 
 
 
Figure 6: Change in blood pressure relative to baseline 
 
 
Bone and mineral metabolism 
No significant treatment effect was evident for markers of bone turnover (bone specific 
alkaline phosphatase and tartrate-resistant acid phosphatase 5b), or for other key molecules 
involved in bone and mineral metabolism (vitamin D metabolites, parathyroid hormone, 
calcium or phosphate). Details are presented in Table 9. 
 
  
59 
 
Table 9. Secondary outcomes - Markers of bone and mineral metabolism 
  Bicarbonate Placebo Treatment effect 
(95%CI)* 
p 
Median TRACP-
5b (IU/L) (IQR) 
Baseline 0.58 (0.29-1.30) n=122 0.88 (0.36 -1.57) n=126 
-0.18 
(-0.43 to 0.08)** 
0.17 12 months 0.72 (0.32-1.16) n=87 0.84 (0.34-1.36) n=75 
24 months 0.46 (0.22-0.85) n=50 0.58 (0.28-1.40) n=56 
 
Median  
Bs-ALP (ug/L) 
(IQR) 
Baseline 14.4 (11.5-19.7) n=124 14.8 (11.4-19.1) n=125 
0.01 
(-0.11 to 0.13)** 
0.83 12 months 13.6 (10.0-18.1) n=89 13.9 (11.5-17.4) n=77 
24 months 13.7 (10.2-19.7) n=55 12.6 (10.3-17.5) n=57 
 
Median PTH 
(pmol/L) (IQR) 
Baseline 16.5 (9.8-26.5) n=103 15.0 (9.8-23.4) n=105 
0.03 
(-0.14 to 0.19)** 
0.75 12 months 17.0 (9.8-30.8) n=82 15.5 (10.2-22.0) n=81 
24 months 14.8 (9.6-31.5) n=58 17.4 (12.2-24.9) n=67 
 
Median 25OHD 
(nmol/L) (IQR) 
Baseline 33 (24-56) n=109 41 (24-67) n=108 
-0.08 
(-0.23 to 0.06)** 
0.24 12 months 35 (22-56) n=88 43 (24-59) n=77 
24 months 42 (23-66) n=53 48 (26-70) n=56 
 
1,25OHD 
(pmol/L) (SD) 
Baseline 57 (23) n=109 54 (24) n=109 
3 (-3 to 9) 0.30 
12 months 61 (40) n=88 55 (23) n=78 
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24 months 62 (29) n=53 58 (28) n=56 
 
Calcium 
(mmol/L) 
Baseline 2.33 (0.13) n=144 2.32 (0.14) n=145 
0.02  
(0.00 to 0.04) 
0.11 
3 months 2.34 (0.13) n=134 2.34 (0.14) n=129 
6 months 2.34 (0.11) n=123 2.34 (0.15) n=115 
12 months 2.35 (0.11) n=107 2.33 (0.12) n=100 
24 months 2.37 (0.11) n=78 2.34 (0.11) n=76 
 
Phosphate 
(mmol/L) 
Baseline 1.26 (0.39) n=142 1.29 (0.27) n=140 
0.02 
(-0.03 to 0.06) 
0.52 
3 months 1.26 (0.26) n=123 1.28 (0.31) n=123 
6 months 1.26 (0.26) n=115 1.23 (0.27) n=106 
12 months 1.27 (0.30) n=106 1.28 (0.36) n=97 
24 months 1.25 (0.27) n=75 1.24 (0.34) n=77 
Repeated measures ANOVA *adjusted for baseline values, minimisation variables, age, sex and CKD category ** log-transformed values 
1,25OHD: 1,25-hydroxyvitamin D. 25OHD: 25-hydroxyvitamin D. Bs-ALP: Bone-specific alkaline phosphatase. PTH: Parathyroid hormone. TRACP-5b: Tartrate-resistant acid phosphatase 5b 
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Other blood markers 
No significant treatment effect was evident for blood haemoglobin and HbA1c level, thyroid 
function, or serum albumin concentrations. Of particular note, no treatment effect was 
evident for serum potassium concentrations. Details are presented in Table 10. 
 
Table 10: Secondary analyses - other blood markers 
  Bicarbonate Placebo Treatment 
effect 
(95% CI)* 
p 
Haemoglobin 
(g/L) 
Baseline 115 (14) n=142 117 (17) n=144 
-0.1  
(-0.4 to 0.2) 
0.48 
3 months 117 (15) n=138 119 (15) n=131 
6 months 118 (13) n=126 118 (16) n=117 
12 months 116 (15) n=112 120 (15) n=101 
24 months 120 (14) n=77 120 (16) n=78 
 
Albumin 
(g/L) 
Baseline 39 (4) n=148 40 (5) n=146 
0 (-1 to 1) 0.67 
3 months 39 (5) n=135 39 (5) n=132 
6 months 39 (5) n=124 39 (5) n=116 
12 months 39 (5) n=109 39 (5) n=100 
24 months 39 (5) n=79 39 (4) n=78 
 
Median TSH 
(IQR) 
Baseline 2.1 (1.5-3.0) n=138 2.1 (1.5-2.8) n=137 
0.07 
(-0.10 to 
0.24)** 
0.39 
3 months 2.2 (1.4-3.1) n=129 1.9 (1.3-2.8) n=124 
6 months 2.1 (1.4-3.3) n=120 2.2 (1.4-3.3) n=109 
12 months 2.2 (1.3-3.6) n=100 2.1 (1.5-2.9) n=93 
24 months 2.5 (1.4-3.1) n=74 2.2 (1.2-3.1) n=75 
 
Potassium 
(mmol/L) 
Baseline 4.9 (0.5) n=149 4.9 (0.5) n=148 
0.0  
(-0.1 to 0.1) 
0.80 
3 months 4.8 (0.5) n=136 4.9 (0.6) n=130 
6 months 4.9 (0.5) n=124 4.8 (0.5) n=116 
12 months 4.8 (0.5) n=112 4.8 (0.5) n=101 
24 months 4.8 (0.6) n=77 4.8 (0.5) n=78 
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HbA1c 
(mmol/mol) 
Baseline 43 (12) n=134 42 (13) n=131 
1 (-1 to 4) 0.38 
3 months 44 (15) n=131 42 (12) n=126 
6 months 45 (15) n=124 43 (13) n=115 
12 months 44 (14) n=103 42 (11) n=92 
24 months 42 (11) n=67 43 (11) n=68 
Repeated measures ANOVA 
*adjusted for baseline values, minimisation variables, age, sex and CKD category 
** log-transformed values 
TSH: Thyroid stimulating hormone. HbA1c: glycosylated haemoglobin  
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Adverse events 
A large number of adverse events (857) were recorded, as is expected for a trial enrolling 
older patients with extensive multimorbidity. 263/300 (88%) of participants experienced at 
least one adverse event. Adverse events were more frequent in the bicarbonate arm (457 vs 
400), with a notable excess of events coded under gastrointestinal (45 vs 25), musculoskeletal 
(28 vs 17), cardiac (32 vs 19), nervous system (24 vs 12) and respiratory (26 vs 14). Full 
details are presented in Table 11.  
 
Table 11. Adverse events by System Order Class (SOC) 
 Bicarbonate 
(n=152) 
Placebo  
(n=148) 
Number with at least one adverse event (%)  131 (86.1) 132 (89.1) 
Number of adverse events: 457 400 
SOC classification – number of events: 
Blood and lymphatic system disorders 5 1 
Cardiac disorders 32 19 
Congenital, familial and genetic disorders 0 1 
Ear and labyrinth disorders 1 1 
Endocrine disorders 1 2 
Eye disorders 6 6 
Gastrointestinal disorders 45 25 
General disorders and administration site conditions 14 20 
Hepatobiliary disorders 0 0 
Immune system disorders 0 0 
Infections and infestations 113 118 
Injury, poisoning and procedural complications 41 32 
Investigations 5 7 
Metabolism and nutrition disorders 19 27 
Musculoskeletal and connective tissue disorders 28 17 
Neoplasms benign, malignant and unspecified (incl 
cysts and polyps) 
9 16 
Nervous system disorders 24 12 
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Psychiatric disorders 1 5 
Renal and urinary disorders 23 23 
Reproductive system and breast disorders 4 1 
Respiratory, thoracic and mediastinal disorders 26 14 
Skin and subcutaneous tissue disorders 16 11 
Surgical and medical procedures 34 30 
Vascular disorders 10 12 
 
For cardiac adverse events, no difference in the number of episodes of decompensated heart 
failure were seen (eight vs ten) but myocardial infarction was more common in the 
bicarbonate arm (ten vs two); details are presented in Table 12. 
 
Table 12. Selected key adverse outcomes of interest 
 Bicarbonate 
(n=152) 
Placebo 
(n=148) 
Deaths (all) (%)  15 (9.9) 11 (7.4) 
Death due to cardiovascular event (%) 4 (2.6) 5 (3.4) 
Death due to end stage renal failure (%) 3 (2.0) 0 (0) 
Commenced dialysis or transplanted (%) 33 (21.7) 33 (22.3) 
Myocardial infarction or acute coronary syndrome (%) 10 (6.6) 2 (1.4) 
Decompensated heart failure or pulmonary oedema (%) 8 (5.3) 10 (6.8) 
Fragility fractures (distal radius, vertebra or neck of 
femur) (%) 
5 (3.3) 2 (1.4) 
   
Number with at least one fall (%) 49 (32.2) 39 (26.4) 
Number of falls 124 70 
Falls rate (per year) (95% CI) 0.99  
(0.61 to 1.38) 
0.72 
(0.25 to 1.19) 
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Need for renal replacement therapy (RRT) 
A total of 66/300 (22%) of participants commenced dialysis or underwent renal 
transplantation during the trial, with no difference between the bicarbonate and placebo arms 
(33 vs 33; p=1.0) (Table 12). Time to event analysis showed no significant difference in 
hazard ratio between groups (HR 1.22, 95% CI 0.74 to 2.02; p=0.43) (Figure 7). Similar 
results were seen for time to a composite outcome of time to either doubling of serum 
creatinine or commencing renal replacement therapy (HR 1.16, 95% CI 0.73 to 1.84; p=0.53) 
 
Figure 7. Time to commencement of renal replacement therapy 
 
Hazard ratio (adjusted for age, sex, CKD category): 1.22 (95%CI 0.74 to 2.02); p=0.43 
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Deaths 
Twenty-six deaths were recorded during the trial, with similar numbers in the bicarbonate and 
placebo arms (15 vs 11; p=0.45) (Table 12). Time to event analysis showed no significant 
difference in hazard ratio between groups (HR 1.30, 95% CI 0.60 to 2.83; p=0.51) (Figure 8) 
 
Figure 8. Time to death 
 
Hazard ratio (adjusted for age, sex, CKD category): 1.30 (95% CI 0.60 to 2.83); p=0.51 
 
Falls 
More participants in the bicarbonate arm reported falling than in the placebo arm but this did 
not reach significance (49 vs 39; p=0.26). Median time to first fall amongst those who fell 
was shorter in the bicarbonate arm (130 days vs 194 days). Cox proportional hazards 
modelling of time to first fall, adjusted for age, sex and CKD category showed a HR of 1.43, 
95% CI 0.94 to 2.20; p=0.09. 
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Meta-analysis of outcomes with BiCARB data included 
 
Figures 9 to 15 show results of the meta-analyses of existing trials of bicarbonate therapy, but 
with BiCARB results added. The increase in serum bicarbonate seen with treatment in the 
BiCARB trial was less than that seen in most other trials, and the favourable effect on 
estimated GFR seen in other trials was also not shown in BiCARB. Meta-analyses including 
BiCARB showed no significant effect of bicarbonate treatment on weight, mid-arm muscle 
circumference, or systolic blood pressure. Heterogeneity was high across all analyses, as 
shown by the high I2 values. 
 
Figure 9. Meta-analysis: Difference in serum bicarbonate (any timepoint) 
 
Mathur22; Brito-Ashurst23; Mahanjan24; Goraya25; Jeong26; Bellasi27; Dubey28  
Figure 10. Meta-analysis: Difference in serum bicarbonate (one year follow up only) 
 
Brito-Ashurst23; Jeong26; Bellasi27; 
Figure 11. Meta-analysis: Difference in estimated GFR (any timepoint) 
 
Brito-Ashurst23; Mahanjan24; Goraya25; Jeong26; Bellasi27; Dubey28  
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Figure 12. Meta-analysis: Difference in estimated GFR (one year follow up only) 
 
Brito-Ashurst23; Jeong26; Bellasi27 
 
Figure 13. Meta-analysis: Difference in systolic blood pressure (any timepoint) 
 
Mathur22; Brito-Ashurst23; Mahanjan24; Goraya25; Bellasi27; Dubey28  
 
Figure 14. Meta-analysis: Difference in weight (any timepoint) 
 
Mathur22; Goraya25; Jeong26; Bellasi27; Dubey28  
 
Figure 15. Meta-analysis: Difference in mid-arm muscle circumference (any timepoint) 
 
Brito-Ashurst23; Jeong26; Dubey28  
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Chapter 5. Cost effectiveness results 
 
Table 13 shows the main resource use and costs per participant for complete cases over the 
first 12 months of follow-up. These initial analyses do not take into account participants who 
dropped out at the point of commencing renal replacement therapy, which are dealt with later 
in this chapter. All cost-effectiveness analyses are based on the Unit Costs reported in 
Appendix 5. The most frequently used resource use item was GP visits (63% to 64% of study 
participants).  The next most frequently used item was outpatient visits (from 60% to 62% for 
nephrology visits, and between 57% and 62% for other outpatient visits).  The most 
expensive resource use item was an inpatient hospital stay, where the mean cost between 
randomised groups varied from £480 (bicarbonate group) to £175 (placebo group).  The least 
frequently used items were physiotherapy, occupational therapy, speech therapy and social 
care.  Totalling all resource use together, costs were lowest over one year amongst 
participants randomised to the placebo group (mean cost £807 per patient) compared to the 
bicarbonate group (£1234 per patient).   
 
Table 14 describes the main resource use and costs per participant for complete cases over 
the first 24 months of follow-up. Due to additional dropout over this extended follow up 
period, the number of complete cases fell to 114 for this analysis. Totalling all resource use 
together, costs were lowest over two years amongst participants randomised to the 
bicarbonate group (mean cost £1184 per patient) compared to the placebo group (mean cost 
£1266 per patient).   
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Table 13. Mean resource use and costs per patient over 12 months follow-up (complete case analysis n=176) 
Resource use item Sodium bicarbonate, n=97 Placebo, n=79 
Resource 
users, 
n (%) 
Mean 
resource use 
(SD) 
Mean cost, 
£ (SD) 
Resource 
users, 
n (%) 
Mean 
resource use 
(SD) 
Mean cost, 
£ (SD) 
NHS hospital care       
Admission days 8 (8) 1.39 (6.24) 480.41 
(2152.51) 
9 (11) 0.51 (1.66) 174.77 
(571.41) 
Day cases 16 (16) 0.24 (0.69) 182.01 
(509.55) 
7 (9) 0.11 (0.39) 83.80  
(288.23) 
Outpatient visits - Nephrology 58 (60) 1.06 (1.09) 200.12 
(333.47) 
49 (62) 1.25 (1.73) 215.24 
(339.65) 
Outpatient visits - Other 60 (62) 1.46 (1.79) 175.43 
(214.70) 
45 (57) 1.54 (1.89) 185.07 
(226.08) 
Day hospital visits 24 (25) 0.55 (1.66) 72.25 (219.30) 19 (24) 0.46 (1.47) 60.26 (194.98) 
Total hospital based care costs   1110.22 
(2261.83) 
  719.15 
(972.64) 
NHS primary care       
GP visits 62 (64) 1.51 (1.64) 57.20 (62.33) 50 (63) 1.38 (1.66) 52.43 (63.03) 
District nurse visits 25 (26) 1.31 (6.36) 48.35 (234.92) 23 (29) 0.62 (1.56) 22.91 (57.73) 
Physiotherapist visits 7 (7) 0.15 (0.74) 8.04 (38.54) 1 (1) 0.01 (0.11) 0.66 (5.85) 
71 
 
Occupational therapist visits 4 (4) 0.04 (0.20) 2.97 (14.40) 1 (1) 0.01 (0.11) 0.91 (8.11) 
Speech therapist visits 0 (0) 0 0 1 (1) 0.01 (0.11) 1.27 (11.32) 
Social service        
Day centre visits 5 (5) 0.10 (0.51) 6.49 (32.13) 2 (3) 0.11 (0.91) 7.18 (57.06) 
Home help/carer visits 1 (1) 0.06 (0.61) 0.94 (9.27) 4 (5) 0.16 (0.78) 2.50 (11.84) 
Total non-hospital based care costs   123.00 
(241.42) 
  87.86 (103.11) 
Total costs   1234.22 
(2334.29) 
  807.01 
(1005.91) 
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Table 14. Mean resource use and costs per patient over 24 months follow-up (complete case analysis n=114) 
Resource use item Sodium bicarbonate, n=59 Placebo, n=55 
Resource 
users, 
n (%) 
Mean 
resource use 
(SD) 
Mean cost, 
£ (SD) 
Resource 
users, 
n (%) 
Mean 
resource use 
(SD) 
Mean cost, 
£ (SD) 
NHS hospital care       
Admission days 6 (10) 0.68 (2.58) 234.02 
(891.50) 
8 (15) 1.05 (4.36) 364.01 
(1505.22) 
Day cases 9 (15) 0.19 (0.47) 137.15 
(347.58) 
8 (15) 0.18 (0.47) 133.75 
(349.39) 
Outpatient visits - Nephrology 40 (68) 1.39 (1.47) 275.45 
(401.21) 
35 (64) 1.56 (2.04) 306.43 
(469.62) 
Outpatient visits - Other 41 (69) 1.93 (2.38) 231.56 
(284.87) 
35 (64) 1.89 (2.27) 226.61 
(271.59) 
Day hospital visits 21 (36) 1.08 (2.62) 143.44 
(346.63) 
15 (27) 0.84 (3.30) 110.59 
(436.16) 
Total hospital based care costs   1021.62 
(1357.52) 
  1141.39 
(1939.44) 
NHS primary care       
GP visits 49 (83) 2.07 (1.79) 78.58 (68.00) 39 (71) 1.98 (2.15) 75.31 (81.60) 
District nurse visits 18 (31) 1.15 (2.88) 42.56 (106.20) 21 (38) 0.94 (2.14) 34.92 (78.96) 
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Physiotherapist visits 6 (10) 0.25 (0.96) 13.23 (49.81) 0 (0) 0 0 
Occupational therapist visits 1 (2) 0.02 (0.13) 1.22 (9.38) 1 (2) 0.02 (0.13) 1.31 (9.72) 
Speech therapist visits 0 (0) 0 0 0 (0) 0 0 
Social service        
Day centre visits 4 (7) 0.39 (2.15) 24.56 (135.43) 2 (4) 0.16 (1.08) 10.31 (68.33) 
Home help/carer visits 2 (3) 0.15 (0.94) 2.32 (14.35) 3 (5) 0.24 (1.00) 3.60 (15.20) 
Total non-hospital based care costs   162.47 
(247.16) 
  125.44 
(144.08) 
Total costs   1184.08 
(1432.11) 
  1266.83 
(1958.68) 
 
 
The above analyses do not account for the costs of renal replacement (dialysis and renal transplantation) for participants who exited the study.  
Over the course of two years follow-up, 66 participants proceeded to dialysis or transplantation, but 49 of these withdrew from the trial, 
commonly at the point of commencing renal replacement therapy. Table 15 includes all dialysis participants alongside the previous complete 
cases.  Their dialysis costs are included and calculated by using information on the type of dialysis and the date dialysis commenced.  The 
remaining health care costs are missing for these participants once they are lost to follow-up.  This table shows that dialysis costs dominate other 
costs amongst both treatment and placebo groups.  Totalling all resource use together, costs were lowest over two years amongst participants 
randomised to the bicarbonate group (mean cost £12125 per participant) compared to the placebo group (£12967 per participant).   
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Table 15. Mean resource use and costs per patient over 24 months follow-up (complete cases and all participants starting renal 
replacement therapy during the trial; n=163) 
Resource use item Sodium bicarbonate, n=82 Placebo, n=81 
Resource 
users, 
n (%) 
Mean 
resource use 
(SD) 
Mean cost, 
£ (SD) 
Resource 
users, 
n (%) 
Mean 
resource use 
(SD) 
Mean cost, 
£ (SD) 
NHS hospital care       
Admission days 11 (13) 2.24 (8.96) 774.55 
(3091.46) 
12 (15) 1.74 (7.87) 600.87 
(2715.09) 
Day cases 14 (17) 0.20 (0.46) 143.54 
(335.79) 
11 (14) 0.16 (0.43) 118.06 
(317.61) 
Outpatient visits - Nephrology 53 (65) 1.32 (1.40) 198.19 
(211.33) 
47 (58) 1.51 (2.25) 226.65 
(338.27) 
Outpatient visits - Other 55 (67) 1.96 (2.39) 235.30 
(286.48) 
46 (57) 1.62 (2.11) 193.82 
(252.50) 
Dialysis visits (Haemodialysis, 
peritoneal dialysis) 
32 (39) 88.55 (136.08) 10344.34 
(14888.34) 
29 (36) 99.18 (168.53) 10982.17 
(17254.63) 
Renal transplant 1 (1) 0.01 (0.11) 154.64 
(1400.35) 
4 (5) 0.05 (0.22) 626.21 
(2764.58) 
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Day hospital visits 27 (33) 0.91 (2.31) 120.94 
(305.51) 
22 (27) 0.80 (3.01) 106.11 
(398.57) 
Total hospital based care costs   11971.5 
(15495.88) 
  12853.88 
(17430.03) 
NHS primary care       
GP visits 62 (76) 1.90 (1.79) 72.29 (68.00) 51 (63) 1.78 (2.08) 67.56 (79.03) 
District nurse visits 24 (29) 1.22 (2.73) 41.43 (100.74) 25 (31) 0.80 (1.94) 29.64 (71.61) 
Physiotherapist visits 7 (9) 0.22 (0.88) 11.42 (45.53) 1 (1) 0.02 (0.22) 1.28 (11.56) 
Occupational therapist visits 2 (2) 0.02 (0.16) 1.76 (11.18) 2 (2) 0.02 (0.16) 1.78 (11.25) 
Speech therapist visits 0 (0) 0 0 0 (0) 0 0 
Social service        
Day centre visits 8 (10) 0.39 (1.88) 24.59 (118.69) 2 (2) 0.11 (0.89) 7.00 (56.35) 
Home help/carer visits 3 (4) 0.13 (0.83) 2.04 (12.59) 4 (5) 0.40 (2.25) 6.01 (34.24) 
Total non-hospital based care costs   153.54 
(219.96) 
  113.33 
(139.86) 
Total costs   12125.03 
(15494.49) 
  12967.15 
(17430.3) 
 
 
 
 
76 
 
 
Tables 16 and 17 show the mean EQ-5D and QALY values over 12 and 24 months for complete cases at both time points.  EQ-5D was lower at 
baseline for the bicarbonate group for the 12 and 24 months analysis (0.73 and 0.74 respectively) compared to the placebo group (0.78 and 0.79 
respectively).  At 12 months follow-up, the mean EQ-5D had increased in the placebo group (0.79) and had fallen in the bicarbonate group 
(0.69).  At 24 months follow-up, the mean EQ-5D had fallen in both groups, by approximately 0.05 in the placebo group and 0.03 in the 
treatment group.  Overall, the total QALYs were higher in the placebo group at both 12 and 24 months follow-up. 
 
Table 16. Mean EQ-5D values and QALYs over 12 months follow-up, by randomised group (complete case analysis n=176) 
Time point Sodium bicarbonate (n=97) 
Mean (SD) 
Placebo (n=79) 
Mean (SD) 
Baseline 0.733 (0.216) 0.779 (0.219) 
3 months 0.720 (0.209) 0.801 (0.152) 
6 months 0.728 (0.190) 0.782 (0.167) 
12 months 0.692 (0.230) 0.787 (0.151) 
Total QALYs over 12 months 0.717 (0.178) 0.788 (0.145) 
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Table 17. Mean EQ-5D values and QALYs over 24 months follow-up, by randomised group (complete case analysis n=114) 
Time point Sodium bicarbonate (n=59) 
Mean (SD) 
Placebo (n=55) 
Mean (SD) 
Baseline 0.740 (0.204) 0.786 (0.203) 
3 months 0.700 (0.223) 0.808 (0.127) 
6 months 0.730 (0.163) 0.802 (0.147) 
12 months 0.707 (0.219) 0.794 (0.136) 
24 months 0.709 (0.254) 0.731 (0.187) 
Total QALYs over 24 months 1.402 (0.185) 1.537 (0.235) 
 
Tables 18 and 19 describe the mean ICECAP values over 12 and 24 months for complete cases at both time points.  In contrast to the EQ-5D and 
QALY analyses, the baseline differences between the groups appear smaller, and for both groups the difference in values between baseline and 
follow-up are smaller relative to the earlier EQ-5D values. Tables 20 and 21 show the mean life satisfaction values for complete cases.  The 
change over time both groups is consistent with the EQ-5D and ICECAP data.   
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Table 18. Mean ICECAP values over 12 months follow-up, by randomised group (complete case analysis n=176) 
Time point Sodium bicarbonate (n=97) 
Mean (SD) 
Placebo (n=79) 
Mean (SD) 
Baseline 0.861 (0.118) 0.875 (0.103) 
3 months 0.867 (0.108) 0.872 (0.110) 
6 months 0.861 (0.125) 0.885 (0.092) 
12 months 0.846 (0.124) 0.892 (0.092) 
 
Table 19. Mean ICECAP values over 24 months follow-up, by randomised group (complete case analysis n=114) 
Time point Sodium bicarbonate (n=59) 
Mean (SD) 
Placebo (n=55) 
Mean (SD) 
Baseline 0.871 (0.105) 0.880 (0.098) 
3 months 0.869 (0.102) 0.870 (0.110) 
6 months 0.868 (0.127) 0.897 (0.080) 
12 months 0.848 (0.120) 0.893 (0.088) 
24 months 0.857 (0.110) 0.873 (0.104) 
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Table 20. Mean life satisfaction values over 12 months follow-up, by randomised group (complete case analysis n=176) 
Time point Sodium bicarbonate (n=97) 
Mean (SD) 
Placebo (n=79) 
Mean (SD) 
Baseline 5.206 (1.607) 5.329 (1.677) 
3 months 5.226 (1.623) 5.405 (1.660) 
6 months 5.000 (1.683) 5.329 (1.708) 
12 months 4.856 (1.633) 5.443 (1.534) 
 
Table 21. Mean life satisfaction values over 24 months follow-up, by randomised group (complete case analysis n=114) 
Time point Sodium bicarbonate (n=59) 
Mean (SD) 
Placebo (n=55) 
Mean (SD) 
Baseline 5.203 (1.517) 5.273 (1.683) 
3 months 5.186 (1.559) 5.582 (1.572) 
6 months 5.000 (1.462) 5.364 (1.747) 
12 months 4.763 (1.568) 5.491 (1.477) 
24 months 4.949 (1.569) 5.055 (1.840) 
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Table 22 shows the adjusted incremental costs and QALYs (ICECAP and life satisfaction in sensitivity analyses) between the groups for the 
complete case analyses at 12 and 24 months, and for the complete cases plus imputed renal replacement cases at 24 months.  The 12 and 24 
months analyses show a statistically significant increase in costs associated with treatment (between £564 and £591 per participant).  The 
addition of the renal replacement patients and their associated costs leads to a higher, but non-significant cost difference (£809 per participant).  
In all three analyses, there is a QALY difference in favour of the placebo group (ranging from 0.05 to 0.08). 
 
Table 22. Adjusteda mean incremental costs, incremental QALYs, and incremental cost-effectiveness ratio between sodium bicarbonate 
vs placebo 
Analysis Incremental mean costs, £ 
(95% CI)b,c,d 
Incremental mean QALYs 
(95% CI)b,c,d 
Mean ICER (£/QALY) 
 
 
Complete cases over 12 
months follow-up (n=176)e  
563.74 (88.18 to 1154.18) -0.047 (-0.078 to -0.015) Dominated 
SA: Lower sodium 
bicarbonate costf 
352.76 (-154.37 to 957.45) -0.047 (-0.078 to -0.015) Dominated 
SA: Lower inpatient stay 
costg 
539.03 (109.13 to 1050.45) -0.046 (-0.078 to -0.015) Dominated 
SA: Using ICECAP valueh 636.20 (187.59 to 1189.24) -0.017 (-0.032 to 0.0001) Dominated 
SA: Using life satisfaction 
valuei 
580.19 (143.38 to 1130.11) -0.396 (-0.733 to -0.059) Dominated 
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Complete cases over 24 
months follow-up (n=114)j 
591.00 (166.29 to 1078.36) -0.083 (-0.166 to -0.005) Dominated 
SA: Lower sodium 
bicarbonate costf 
242.59 (-179.63 to 720.27) -0.083 (-0.166 to -0.005) Dominated 
SA: Lower inpatient stay 
costg 
593.74 (191.37 to 1072.07) -0.083 (-0.166 to -0.005) Dominated 
SA: Using ICECAP valueh 598.87 (215.69 to 1052.43) -0.051 (-0.095 to -0.010) Dominated 
SA: Using life satisfaction 
valuei 
682.44 (257.28 to 1142.63) -0.974 (-1.762 to -0.190) Dominated 
 
Complete cases over 24 
months follow-up and all 
participants starting renal 
replacement therapy during 
the trial (n=161)j 
808.93 (-4124.71 to 5411.89) -0.074 (-0.151 to -0.003) Dominated 
SA: Lower sodium 
bicarbonate costf 
534.61 (-4385.90 to 5149.69) -0.074 (-0.150 to -0.003) Dominated 
SA: Lower inpatient stay 
costg 
817.21 (-4097.90 to 5415.22) -0.073 (-0.151 to -0.001) Dominated 
SA: Using ICECAP valueh,k 422.08 (-4091.74 to 4629.60) -0.046 (-0.090 to -0.002) Dominated 
SA: Lower dialysis costl 600.26 (-3560.78 to 4379.06) -0.075 (-0.154 to -0.001) Dominated 
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SA: Higher dialysis costm 899.41 (-4327.11 to 5714.04) -0.074 (-0.156 to 0.002) Dominated 
SA: Using life satisfaction 
valuei,n 
928.18 (-4373.23 to 5729.68) -0.072 (-1.366 to 0.002) Dominated 
Notes 
a Adjusted for baseline differences (age, gender, stage of CKD, baseline EQ-5D health utility score and baseline cost). 
b Bootstrapped non-parametric 95% confidence interval (2.5th/97.5th percentile). 
c Generalised linear model with γ distribution and power 0.65 link function to estimate incremental costs and ordinary least squares regression to estimate 
incremental QALYs (complete cases). 
d 
 
 
 
e 
f 
g 
h 
i 
j 
k 
l 
m 
n 
Generalised linear model with Gaussian distribution and power 0.5 link function to estimate incremental costs and ordinary least squares regression to estimate 
incremental QALYs (complete cases + all participants starting renal replacement therapy during the trial). For incomplete cases, missing cost data were assumed 
to be zero and missing EQ-5D data were imputed by carrying forward the last observation. Two participants from placebo group without EQ-5D data were 
excluded from the analysis. 
Applied average cost of sodium bicarbonate 500 mg, £0.54/day. 
Applied average cost of three generic sodium bicarbonate 500 mg with the lowest price, £0.14/day. 
Applied average of lower quartile unit cost for non-elective inpatient and elective inpatient bed days, £287/day. 
Adjusted for baseline differences (age, gender, stage of CKD, baseline ICECAP value and baseline cost). 
Adjusted for baseline differences (age, gender, stage of CKD, baseline life satisfaction value and baseline cost). 
Discounted at 3.5% per year. 
Two participants from bicarbonate group without any ICECAP data were excluded from the analysis, n=159. 
Applied average of lower quartile unit cost for haemodialysis (£134/visit) and peritoneal dialysis (£66/visit). 
Applied average of upper quartile unit cost for haemodialysis (£180/visit) and peritoneal dialysis (£77/visit). 
Two participants (1 from each group) without any life satisfaction data were excluded from the analysis, n=159. 
Abbreviations 
 QALYs, quality-adjusted life-years; ICER, incremental cost-effectiveness ratio; SA, sensitivity analysis; ICECAP: Investigating Choice Experiments for the 
preferences of older people CAPability tool; CKD, chronic kidney disease. 
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Figure 16 shows the scatterplot and the associated cost-effectiveness acceptability curves for 
the three analyses.  Without the inclusion of dialysis costs, there is almost zero probability of 
the intervention being cost-effective at conventional thresholds of willingness to pay. For the 
analysis with the inclusion of renal replacement costs, there is more uncertainty over cost 
differences, with the intervention having a probability of being cost-effective of between 0.4 
and 0.1. At conventional values of £30,000 per QALY, there is a 14% probability of the 
treatment being deemed cost-effective. 
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Figure 16. Scatterplot and cost-effectiveness acceptability curve of incremental cost 
difference and incremental QALY difference between randomised groups 
a) Complete cases over 12 months follow-up (n=176) 
  
b) Complete cases over 24 months follow-up (n=114) 
  
c) Complete cases and all participants starting renal replacement therapy during the trial over 24 months follow-
up (n=161) 
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Sensitivity analyses were conducted to explore the impact of different unit cost assumptions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Sensitivity analyses of incremental cost difference and incremental QALY or 
ICECAP difference between randomised groups – 12 months 
a) Complete cases over 12 months follow-up (n=176), sensitivity analysis - lower sodium bicarbonate 
costs 
  
b) Complete cases over 12 months follow-up (n=176), sensitivity analysis - lower inpatient stay costs 
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c) Complete cases over 12 months follow-up (n=176), sensitivity analysis – ICECAP values 
 
NA 
Figure 18. Sensitivity analyses of incremental cost difference and incremental ICECAP 
difference between randomised groups – 24 months 
a) Complete cases over 24 months follow-up (n=114), sensitivity analysis – lower sodium bicarbonate 
costs 
  
b) Complete cases over 24 months follow-up (n=114), sensitivity analysis – lower inpatient stay costs 
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c) Complete cases over 24 months follow-up (n=114), sensitivity analysis – ICECAP values 
 
NA 
 
Figure 19. Sensitivity analyses of incremental cost difference and incremental life 
satisfaction difference between randomised groups – 12 and 24 months 
 Complete cases over 12 months follow-up (n=176) – life satisfaction value 
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 Complete cases over 24 months follow-up (n=114)  – life satisfaction value 
 
d) Complete cases over 24 months follow-up and all participants starting renal replacement therapy 
during the trial (n=159)  – life satisfaction value 
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Chapter 6. Discussion 
Key findings 
This pragmatic, multicentre, randomised controlled trial found that administration of oral 
sodium bicarbonate using a dose regimen similar to that currently used in UK practice did not 
improve physical function or quality of life, and did not slow down deterioration in renal 
function compared to placebo in older people with CKD category 4 or 5 and serum 
bicarbonate concentrations of <22 mmol/L. Consistent with these findings, health economic 
analysis showed that bicarbonate use was less cost-effective than placebo. Analyses of 
markers of bone and vascular health found no evidence that bicarbonate improved bone 
health; blood pressure was neither raised nor lowered significantly by bicarbonate therapy 
compared to placebo. Bicarbonate therapy was moderately well adhered to; overall adverse 
event rates including falls were higher in the bicarbonate group than in the placebo group 
despite the two groups being balanced for most morbidities and medications at baseline. 
Bicarbonate is known to cause gastrointestinal side effects, such as nausea and bloating, and 
this was reflected in the higher rate of gastrointestinal side effects. Higher rates of cardiac, 
respiratory and neurological adverse events were seen in the bicarbonate supplementation 
group, but lower rates of cancer. These differences may be due to chance, but pooling of 
these data with results from other trials of bicarbonate is required to investigate the safety 
profile further. The excess of cardiovascular events was driven by higher rates of myocardial 
infarction, but the mechanism underpinning this is not clear, as blood pressure was not 
increased in the bicarbonate group. Fluid overload due to a sodium load in patients with heart 
failure or other cardiovascular disease was a concern at the planning stage of the trial, but no 
difference in these events was seen between the two groups, and decompensated heart failure 
events were not responsible for the observed excess of cardiovascular events. 
 
Although rates of death and renal replacement were similar in both arms, it is concerning that 
several measures of physical function were in fact worse in the bicarbonate arm than the 
placebo arm. This is despite adjusting for baseline values. Differential dropout is unlikely to 
explain this finding as dropout rates were similar in each arm. Although the difference on 
repeated measures for the SPPB was of borderline clinical significance, the degree of 
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difference for grip strength and for the six minute walk distance is likely to be of clinical 
significance.55 These findings, in conjunction with the higher adverse event rate seen in the 
bicarbonate arm, call into question not only the efficacy, but the safety of using bicarbonate 
in this target patient population.  
 
Results in context 
For many of the outcomes measured in BiCARB, it was not possible to combine the data with 
that from previous trials. This was particularly the case for physical function and quality of 
life data, which have not been a focus for outcome measurement in previous trials. As this is 
the first trial to examine the effects of bicarbonate supplementation on physical function 
measures, it is not possible to tell if the observed worsening in physical function measures 
with bicarbonate was a chance finding or a real effect. Existing observational data suggests a 
relationship between higher serum bicarbonate and better physical function,14,15 and a recent 
meta-analysis of studies testing the effect of bicarbonate on elite athletic performance found a 
weak, but significant positive effect of bicarbonate on performance of middle-distance 
athletes.56 We were unable to find evidence of a biological mechanism that would 
convincingly explain why bicarbonate supplementation should worsen physical function.  
 
Adding the results of the BiCARB trial to the meta-analysis findings showed no overall effect 
of bicarbonate on weight or mid-arm muscle circumference. Similarly, the overall effect on 
systolic blood pressure, both overall or when confining analyses to one year outcomes, 
showed no significant worsening of blood pressure with bicarbonate treatment. Overall 
estimates of the effect of bicarbonate on bicarbonate levels and eGFR when combining all 
available trials in meta-analysis still suggest a modest benefit, but the results are highly 
heterogeneous, suggesting that the population studied in BiCARB may respond differently 
for these outcomes than other populations studied to date, who differ in both predominant 
aetiology, age, and ethnic background. It is also important to note that there was considerable 
heterogeneity in length of follow up, treatment schedules and whether patients, clinicians and 
study teams were masked to treatment allocation. Restricting analyses to a single time point 
(12 month follow up) removes some, but not all of this heterogeneity. In addition, measures 
of variance for outcomes in some trials included in the meta-analysis were much lower than 
would be expected, raising the possibility that standard errors had been reported rather than 
standard deviations as advertised in the papers. It is not possible to verify this without access 
to individual participant level data but the use of standard errors would lead to these trials 
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being given undue weight in the meta-analysis results. Results from these meta-analyses 
should be treated with caution due to these limitations. 
 
Generalisability and limitations to generalisability 
Trials of oral bicarbonate therapy to date have targeted a wide range of groups – those with 
bicarbonate in the normal range as well as those with low bicarbonate, those with specific 
renal conditions (e.g. CKD of unknown origin, hypertensive nephropathy with albuminuria), 
or those with moderate renal disease (CKD category 3), which is not a usual target for 
bicarbonate therapy. This trial is distinctive in targeting older people, who form the majority 
of patients with CKD in the UK and most other high-income countries. It included patients 
from across the UK, with advanced CKD (thus reflecting the usual target group for 
bicarbonate therapy in practice). 
 
The increase in serum bicarbonate seen in the bicarbonate arm compared to placebo was 
modest, and it could be argued that the lack of benefit on the main study outcomes is 
unsurprising given this modest increment in serum bicarbonate. However, the increase in 
bicarbonate was consistent with that seen in previous trials including a recent trial published 
only in abstract form,57 albeit at the lower end of the range of responses seen. Furthermore, 
several trials demonstrating larger increases in serum bicarbonate used open-label designs 
and titrated treatment to reach specific bicarbonate targets. In current UK practice, doses of 
1.5 grams to 3 grams of oral bicarbonate per day are commonly used, and our treatment 
strategy reflects this practice. Whilst we cannot therefore rule out a beneficial effect of higher 
doses of bicarbonate, our results support the contention that current UK practice for 
bicarbonate replacement in CKD does not improve a wide range of outcomes in older patients 
with advanced CKD. Increasing the dose of sodium bicarbonate beyond 3 grams per day risks 
further worsening of adherence; bicarbonate tablets are large and difficult for older people to 
swallow. In addition, higher doses run the risk of increasing the rate of adverse events still 
further – particularly gastrointestinal side effects. Nevertheless, treatment regimens (either 
using bicarbonate or newer acid-binding agents) that produce greater increases in serum 
bicarbonate concentration could still carry benefit and require testing. 
 
The commissioning brief and trial design focussed on patients with mild degrees of acidosis. 
Few participants were enrolled with serum bicarbonate concentrations below 18mmol/L, as 
most patients with bicarbonate concentrations this low are treated with bicarbonate already. 
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We are therefore unable to comment on the potential benefits of treating more severe levels 
of acidosis in this population. 
 
Other limitations 
Key limitations of the work were the high proportion of white patients. One previous UK trial 
that showed positive effects enrolled predominantly participants of South Asian and African 
ethnicity, and we do not have sufficient participants to exclude a beneficial effect in these 
ethnic groups. The trial enrolled a preponderance of men, which may limit the 
generalisability of the results given the relative underrepresentation of women. The study 
population had relatively stable CKD, with low rates of progression to end-stage kidney 
disease, and this was consistent with the low levels of proteinuria in the study population. 
 
The original target for recruitment for this trial (380 participants) was not reached despite 
recruiting from 27 UK sites. This was in part due to a lack of clinical equipoise; surveys of 
UK practitioners performed by the trial team during the trial suggested that most 
nephrologists were treating mild degrees of acidosis with bicarbonate already thus reducing 
the pool of eligible participants. Despite this, revised sample size calculations performed to 
inform the decision to cease recruitment suggested that the sample size randomised (n=300) 
had 87% power to detect a one-point difference in the primary outcome of the short physical 
performance battery. Our results exclude a one-point improvement in the primary outcome by 
a wide margin, and also exclude a more conservative 0.5 point improvement (posited by 
some researchers as an MCID for the SPPB).55  
 
Bicarbonate levels in the placebo group rose gradually over time, which limited the contrast 
in bicarbonate levels between the groups. Some of this increase is likely to have been due to 
regression to the mean, some due to dropout of participants who started renal replacement 
therapy (who are more likely to have worse renal function and worse acidosis) but some may 
also be due to individuals in the placebo group stopping study medication and starting 
unblinded bicarbonate therapy as part of routine practice. The impact of starting bicarbonate 
is likely to have been small though – only 18 people in the placebo group stopped study 
medication in order to start bicarbonate. 
 
The majority of participants that commenced renal replacement therapy dropped out from 
follow up at the point of commencing renal replacement therapy. The costs of ongoing renal 
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replacement therapy for these participants could not be directly captured as part of the main 
health economics analysis, and quality of life after starting RRT was also not ascertained for 
participants who dropped out of the trial. Renal replacement costs were included in one of the 
economic analyses – but other associated costs for these patients were not captured.  The 
same number of participants commenced renal replacement therapy in each arm (33 in each 
arm) and the time to commencement was slightly shorter in the bicarbonate arm.  The 
economic analysis is consistent with this finding, showing that overall costs were higher in 
the bicarbonate arm. It is still possible that unmeasured costs associated with, but not 
attributable to renal replacement therapy (for example additional inpatient stays, additional 
adverse events) could still influence the economic analysis. However, the fact that more 
adverse events were seen during the trial in the bicarbonate arm suggests that any 
unmeasured events would tend to accentuate, rather than reverse, the results of the health 
economic analysis as presented. Similarly, small differences between groups in the time spent 
avoiding commencement of renal replacement therapy are likely to have large effects on 
costs. However, the analysis of time to commencement of renal replacement therapy suggests 
that participants in the bicarbonate group started renal replacement sooner, and the addition 
of these renal replacement costs reinforced, rather than overturned, the results of the main 
economic analyses. 
 
Strengths 
Key strengths of this trial were its comparatively large size, sufficient follow up time, 
participant, clinician and researcher masking, and broad inclusion criteria. In contrast to 
almost all previous trials, our use of a placebo control reduced the opportunities for bias, 
particularly with respect to decision making around the timing of commencement of renal 
replacement therapy. An additional key strength was the broad range of outcome measures 
examined, with a particular focus on physical function and quality of life. These are the 
outcomes that older people report being most important to them, and this focus is of 
particular importance in this group of patients with extensive multimorbidity. A narrow focus 
on a single disease – even in patients with advanced CKD – is inappropriate in this group, 
and considering physical function and quality of life enables an assessment of the overall 
benefit of treatment to patients in a way that organ-specific measures do not. 
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Chapter 7. Conclusions 
Implications for healthcare 
Bicarbonate is currently in widespread use to treat mild degrees of acidosis in patients with 
stage 4 or 5 CKD. This is largely on the basis of observational data suggesting an association 
between acidosis and a range of deleterious outcomes including accelerated decline in renal 
function, bone health, physical function and vascular health. Little trial evidence supports 
current practice, a state of affairs that guidelines acknowledge.31,32 Our results suggest that at 
least in this predominantly male and white population of older patients with CKD category 4 
and 5, 1.5 grams to 3 grams per day of oral bicarbonate did not produce any health benefits 
and may be associated with net harms compared with placebo. Whilst other indications for 
control of acidosis exist (for example high potassium concentrations), evidence from the 
current trial suggests that the additional cost, treatment burden and side effects of oral 
bicarbonate may not justify its use in older people with advanced CKD and mild acidosis. 
 
Suggestions for future research 
A number of other trials of bicarbonate therapy are currently in progress or are in the process 
of being published.57-59 These trials target a range of different CKD severities (CKD 3b to 5), 
a range of entry serum bicarbonate concentration (<21 mmol/L, >18 mmol/L and 20-25 
mmol/L) and for two of the trials, a strategy of dose adjustment to keep serum bicarbonate 
>24 mmol/L is employed. None of these trials targets older people as a specific group. Once 
data are available from these trials, we recommend that the key research priority should be to 
combine data from these trials. We therefore make the following suggestions for further 
research: 
 
- An individual participant meta-analysis should be conducted, examining the effects of 
bicarbonate therapy on physical function, quality of life, renal function and 
progression to renal replacement therapy, anthropometry, bone and vascular health 
- Importantly, such a meta-analysis should also seek to pool adverse events, particularly 
cardiovascular events, and should also seek to identify characteristics of those most 
likely to respond to bicarbonate therapy 
- The results from BiCARB call into question the usefulness of bicarbonate in other 
groups where it is currently used routinely. Depending on the results of meta-
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analyses, it may be necessary to formally test the effectiveness of bicarbonate therapy 
in other groups with CKD, for example younger patients. 
- Alternative methods to manage acidosis in advanced CKD need to be tested. A pilot 
study of dose-titration to target would be one alternative way to approach low 
bicarbonate levels once it is clearer which subgroups (if any) are more likely to 
benefit. Novel methods of managing acidosis such as non-absorbed hydrochloric acid 
binders also require testing. 
 
A final recommendation is that clinical trials in disease areas that affect predominantly older 
people need to be designed and executed in such a way that older people are well represented, 
and should use outcome measures that are important to older people.60 The BiCARB trial 
shows how this can be done successfully in the field of chronic kidney disease; there is a 
need to ensure that similar outcomes and methods are applied to other questions within the 
field of chronic kidney disease, but also more widely in other organ-specific fields of clinical 
practice. The evidence base underpinning design and delivery of trials that are right for older 
people is very limited; research is needed on how best to design trials to include older people, 
how to retain and recruit older people successfully, and on the use of outcomes that are 
relevant to older people with multimorbidity. 
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Appendices 
Appendix 1. Search strategy for systematic review – MedLine search 
 
1 exp BICARBONATES [MESH] 24176 
2 exp Sodium bicarbonate [MESH] 4387 
3 Bicarbonates [mp] 21707 
4 1 or 2 or 3 24458 
5 Chronic kidney disease [mp] 43554 
6 Renal insufficiency, chronic [MESH[ 17753 
7 CKD [mp] 24465 
8 Kidney failure, chronic [MESH] 89084 
9 5 or 6 or 7 or 8 129377 
10 4 and 9 826 
11 Limit 10 to (English language and RCT) 77 
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Appendix 2: Systematic Review findings 
Table A2.1: Characteristics of included studies 
Study Location N Mean 
age 
CKD category Bicarbonate 
level entry 
criterion 
Intervention Comparator Duration Primary 
outcome 
Mathur22 
2006 
India 40 41 “Mild to 
moderate” CKD 
(creatinine 
<442umol/L). 
CKD category not 
specified 
Not specified Oral bicarbonate 
1.2mEq/kg in 3 
divided doses, 
titrated to maintain 
serum bicarbonate in 
range 22-26mmol/L 
Placebo 3 months Not specified 
De Brito-
Ashurt23 
2009 
UK 134 55 4 or 5 Bicarbonate 
>16mmol/L 
and 
<19mmol/L 
Oral bicarbonate 
600mg 3x/day, 
increased as needed 
to maintain serum 
bicarbonate 
>23mmol/L 
Usual care 2 years Decline in 
creatinine 
clearance of 
>3ml/min/year 
Mahajan24 
2010 
USA 120 51 2 with 
hypertension and 
macroalbuminuria 
Total CO2 
>24.5mmol/L 
Oral bicarbonate 
0.5mEq/kg lean body 
weight 
Placebo 5 years eGFR decline 
rate 
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Jeong25 
2014 
South 
Korea 
80 55 4 or 5 Total CO2 
<22mmol/L 
Oral bicarbonate 1g 
3x/day, titrated to 
maintain serum 
bicarbonate 
>22mmol/L 
Usual care 12 months eGFR 
Goraya26 
2014 
USA 108 54 3 Total CO2 >22 
and 
<24mmol/L 
Oral bicarbonate 
0.3mEq/Kg lean 
body weight in three 
divided doses 
Usual care 3 years eGFR 
Bellasi27 
2016 
Italy 145 65 3b or 4; in 
patients with 
T2DM 
Bicarbonate 
<24mmol/L 
Oral bicarbonate 
0.5mEq/kg twice 
daily, until serum 
bicarbonate 24-
28mmol/L 
Usual care 12 months Insulin 
resistance 
Dubey28 
2018 
India 188 50 3 and 4 Bicarbonate 
<22mmol/L 
Oral bicarbonate 
titrated with weekly 
monitoring 
Usual care 6 months Mid arm 
muscle 
circumference 
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Figure A2.1: Quality assessment of included studies 
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Meta-analysed outcomes; before reporting of BiCARB trial results 
 
Figure 2: Serum bicarbonate (any timepoint) 
 
Mathur22; Brito-Ashurst23; Mahanjan24; Goraya25; Jeong26; Bellasi27; Dubey28  
 
 
Figure 3: Serum bicarbonate (1 year follow up only) 
 
Brito-Ashurst23; Jeong26; Bellasi27 
 
 
Figure 4: Estimated GFR (any timepoint) 
 
Brito-Ashurst23; Mahanjan24; Goraya25; Jeong26; Bellasi27; Dubey28  
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Figure 5: Estimated GFR (1 year follow up only) 
 
Brito-Ashurst23; Jeong26; Bellasi27 
 
Figure 6: Systolic blood pressure (any timepoint) 
 
Mathur22; Mahanjan24; Goraya25; Bellasi27; Dubey28  
 
Figure 7: Weight (any timepoint) 
 
Mathur22; Goraya25; Jeong26; Bellasi27; Dubey28  
 
Figure 8: Mid-arm muscle circumference (any timepoint) 
 
Brito-Ashurst23; Jeong26; Dubey28  
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Appendix 3. List of secondary outcomes in the BiCARB trial and details of tests used 
 
Test Test details 
Six minute walk distance Measured on a 25m course with standardised 
encouragement 
Handgrip strength Maximum value in dominant hand to nearest 0.1kg 
(best of 3). Measured using Takei Grip-D 
dynamometer 
Weight To nearest 0.1kg 
Mid-arm muscle circumference Calculated as mid-arm circumference (cm) – (π x 
triceps skinfold thickness in cm) 
Triceps skinfold thickness Using callipers, measured to nearest mm 
Mid-thigh circumference To nearest 0.1cm, measured using tape measure 
EQ-5D-3L score Collected using standard published questionnaire. 
Results mapped to UK preference weights before 
analysis 
EQ-5D thermometer Collected using standard published questionnaire 
KDQoL questionnaire Collected using standard published questionnaire 
Estimated glomerular filtration 
rate 
Derived from serum creatinine via MDRD4 equation 
Creatinine Analysed by local NHS laboratories at each site 
Cystatin C Analysed by central laboratory (Canterbury) 
Turbidimetric immunoassay (Abbott Architect 
analyser).  
Analytical CV 4.7%, 1.8% and 1.5% at 
concentrations of 63, 170 and 645 umol/L 
respectively. 
Urinary albumin/creatinine ratio Analysed by central laboratory (Canterbury) 
Urinary albumin: Turbidimetric immunoassay and 
Urinary creatinine: Enzymatic assay, both on an 
Abbott Architect analyser 
Albumin analytical CVs: 6.4% and 2.5% at 
concentrations of 23.3 and 72.2 mg/L respectively. 
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Creatinine analytical CVs: 1.1% and 0.9% at 
concentrations of 5.3 and 11.3 mmol/L respectively. 
Tartrate-resistance acid 
phosphatase- 5b 
Analysed by central laboratory (Dundee) 
ELISA assay (CUSABIO, Houston, TX, USA). 
Intra-assay CV: 14.3% using plasma pool. 6.3% 
using 2.5mIU/ml standard 
Inter-assay CV: 6.9% using plasma pool 
Bone-specific alkaline 
phosphatase 
Analysed by central laboratory (Dundee) 
Sandwich chemiluminescence assay (Diasorin, Italy) 
Mean intra-assay CV: 9.1% using plasma pool 
Inter-assay CV 8.5-11.5% using control standards 
PTH Analysed by local NHS laboratories at each site 
25-hydroxyvitamin D Analysed by central laboratory (Guys and St 
Thomas) 
Chemiflex chemiluminescence microparticle 
immunoassay (Abbott Diagnostics, Lake Forest, IL, 
USA). 
Inter-assay CV: 6.6%, 4% and 3% at serum 25OHD 
concentrations of 13, 25 and 50 nmol/L respectively. 
1,25-hydroxyvitamin D Analysed by central laboratory (Guys and St 
Thomas) 
Immunoextraction followed by chemiluminescence 
immunoassay on IDS-iSYS system ( 
Immunodiagnostic Systems Holdings PLC, Tyne & 
Wear, UK).  
Inter-assay CV was 9.5 % and 10.25 at 1,25OHD 
concentrations of 58 and 103 pmol/L. 
NT-pro-B-type natriuretic peptide Analysed by central laboratory (Dundee) 
ELISA assay (Meso Scale Discovery, Rockville, 
Maryland, USA). 
Mean intra-assay CV: 4.7% across all samples; 9.2-
11.7 using control standards 
Inter-assay CV 2.3-5.3% using control standards 
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Haemoglobin Analysed by local NHS laboratories at each site 
Total cholesterol Analysed by local NHS laboratories at each site 
Serum albumin Analysed by local NHS laboratories at each site 
TSH Analysed by local NHS laboratories at each site 
Serum Potassium Analysed by local NHS laboratories at each site 
Serum calcium Adjusted for serum albumin concentration. Analysed 
by local NHS laboratories at each site 
Serum Phosphate Analysed by local NHS laboratories at each site 
HbA1c Analysed by local NHS laboratories at each site 
Serum bicarbonate Analysed by local NHS laboratories at each site 
Systolic blood pressure 
 
Measured using OMRON 705CP-II (HEM-759-E2) 
oscillometric device. Three readings supine after 5 
minutes rest; mean of 2nd and 3rd reading used as 
blood pressure reading 
Diastolic blood pressure 
Falls Collected using monthly self-report diaries 
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Appendix 4. Recruitment 
 
Figure 1: Monthly recruitment rate 
 
 
Figure 2: Cumulative recruitment 
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Table 1: Recruitment by site 
Site Month started recruitment Number randomised 
Aberdeen May 2013 10 
Canterbury May 2013 38 
Dundee* May 2013 0 
Guy’s and St Thomas’* May 2013 1 
Salford May 2013 51 
Sheffield May 2013 11 
Preston Sept 2013 22 
Portsmouth Aug 2013 23 
Mid Essex Aug 2013 22 
Manchester Dec 2013 19 
Leicester Dec 2013 28 
North Staffs Feb 2014 4 
Pennine Dec 2013 6 
Wolverhampton Feb 2014 15 
Highland Feb 2014 5 
Wirral May 2014 1 
Sussex Jul 2014 8 
Exeter Mar 2015 3 
Plymouth Jul 2014 4 
Southend Sep 2014 8 
Fife Mar 2015 7 
Gloucester Oct 2015 3 
Birmingham Jul 2015 5 
Imperial Jul 2016 3 
Colchester Nov 2016 0 
Basildon Nov 2016 1 
TOTAL  300 
 
*Closed early due to poor recruitment (Dundee) and regulatory issues (Guy’s & St Thomas’) 
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Appendix 5: Unit costs for health economic analysis 
 
Unit costs applied to value health care resource use (£, 2016/17 UK prices) 
 
Resource Unit Source Basis of estimate Cost (£) 
NHS health care resource 
use  
    
Inpatient stay Day NHS Reference 
Costs52 
Non-elective inpatient and elective inpatient (mean cost over 
these two categories) 
345 
Day case Visit NHS Reference 
Costs 
Day Case 736 
Outpatient - Nephrology Visit NHS Reference 
Costs 
WF01A Non-Admitted Face-to-Face Attendance, Follow-up 
361 Nephrology, WF01B Non-Admitted Face-to-Face 
Attendance, First 361 Nephrology (mean over consultant led 
and non-consultant led) 
150 
Outpatient - Other Visit NHS Reference 
Costs 
Outpatient Attendances (weighted average of all outpatient 
attendances) 
120 
Haemodialysis Visit NHS Reference 
Costs 
LD01A Hospital Haemodialysis or Filtration, with Access via 
Haemodialysis Catheter, 19 years and over, LD02A Hospital 
Haemodialysis or Filtration, with Access via Arteriovenous 
Fistula or Graft, 19 years and over, LD02A Hospital 
167 
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Haemodialysis or Filtration, with Access via Arteriovenous 
Fistula or Graft, 19 years and over, LD03A Hospital 
Haemodialysis or Filtration, with Access via Haemodialysis 
Catheter, with Blood-Borne Virus, 19 years and over, LD04A 
Hospital Haemodialysis or Filtration, with Access via 
Arteriovenous Fistula or Graft, with Blood-Borne Virus, 19 
years and over, LD05A Satellite Haemodialysis or Filtration, 
with Access via Haemodialysis Catheter, 19 years and over, 
LD06A Satellite Haemodialysis or Filtration, with Access via 
Arteriovenous Fistula or Graft, 19 years and over, LD07A 
Satellite Haemodialysis or Filtration, with Access via 
Haemodialysis Catheter, with Blood-Borne Virus, 19 years 
and over, LD08A Satellite Haemodialysis or Filtration, with 
Access via Arteriovenous Fistula or Graft, with Blood-Borne 
Virus, 19 years and over, LD09A Home Haemodialysis or 
Filtration, with Access via Haemodialysis Catheter, 19 years 
and over, LD10A Home Haemodialysis or Filtration, with 
Access via Arteriovenous Fistula or Graft, 19 years and over 
(mean cost over these ten categories) 
Peritoneal dialysis Session NHS Reference 
Costs 
LD11A Continuous Ambulatory Peritoneal Dialysis, 19 years 
and over, LD12A Automated Peritoneal Dialysis, 19 years 
76 
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and over, LD13A Assisted Automated Peritoneal Dialysis, 19 
years and over (mean cost over these three categories) 
Renal transplant Episode NHS Reference 
Costs 
LA01A Kidney Transplant, 19 years and over, from Cadaver 
Non-Heart-Beating Donor, LA02A Kidney Transplant, 19 
years and over, from Cadaver Heart-Beating Donor, LD03A 
Kidney Transplant, 19 years and over, from Live Donor 
(mean cost over these three categories) 
12681 
Day hospital Visit NHS reference 
cost 
DCFRAD Day Care Facilities Regular Attendances, Elderly 
Patients 
132 
Day centre Visit Curtis 201753 Local authority own-provision day care for older people 63 
General Practitioner Visit Curtis 2017 9.22 minutes consultation, including qualification and direct 
staff 
38 
Home help/professional 
home carer 
Visit Curtis 2017 
 
Assume visit lasts 30 minutes54 
Face-to-face, independent sector home care provided for 
social services (weighted mean over weekday, day-time 
weekend, night-time weekday and night-time weekend) 
15 
District nurse Visit NHS Reference 
Costs 
N02AF District Nurse, Adult, Face-to-Face 37 
Physiotherapist Visit NHS Reference 
Costs 
WF01A Non-Admitted Face-to-Face Attendance, Follow up 
650 Physiotherapy, WF01B Non-Admitted Face-to-Face 
Attendance, First 650 Physiotherapy, AHP Allied Health 
52 
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Professionals A08A1 Physiotherapist, Adult, One to One, 
AHP Allied Health Professionals A08AG Physiotherapist, 
Adult, Group (mean over these four categories) 
Occupational therapist Visit NHS Reference 
Costs 
WF01A Non-Admitted Face-to-Face Attendance, Follow up 
651 Occupational Therapy, WF01B Non-Admitted Face-to-
Face Attendance, First 651 Occupational Therapy, AHP 
Allied Health Professionals A06A1 Occupational Therapist, 
Adult, One to One, AHP Allied Health Professionals A06AG 
Occupational Therapist, Adult, Group (mean cost over these 
four categories) 
72 
Speech therapist Visit NHS Reference 
Costs 
WF01A Non-Admitted Face-to-Face Attendance, Follow up 
652 Speech and Language Therapy, WF01B Non-Admitted 
Face-to-Face Attendance, First 651 Speech and Language 
Therapy, AHP Allied Health Professionals A13A1 Speech 
and Language Therapist, Adult, One to One, AHP Allied 
Health Professionals A13AG Speech and Language 
Therapist, Adult, Group (mean cost over these four 
categories) 
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Appendix 6. Health economic sensitivity analyses 
 
Figure 1. Sensitivity analyses of incremental cost difference and incremental ICECAP 
difference between randomised groups – 24 months 
a) Complete cases over 24 months follow-up (n=114), sensitivity analysis – lower sodium bicarbonate 
costs 
  
b) Complete cases over 24 months follow-up (n=114), sensitivity analysis – lower inpatient stay costs 
  
c) Complete cases over 24 months follow-up (n=114), sensitivity analysis – ICECAP values 
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NA 
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Figure 2. Sensitivity analyses of incremental cost difference and incremental life 
satisfaction difference between randomised groups – 12 and 24 months 
a) Complete cases over 12 months follow-up (n=176) – life satisfaction value 
 
  
b) Complete cases over 24 months follow-up (n=114)  – life satisfaction value 
 
c) Complete cases over 24 months follow-up and all participants starting renal replacement therapy 
during the trial (n=159)  – life satisfaction value 
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Figure 3. Sensitivity analyses of incremental cost difference and incremental QALY or 
ICECAP difference between randomised groups – Complete cases over 24 months 
follow-up and all participants starting renal replacement therapy during the trial   
 
a) Complete cases over 24 months follow-up and all participants starting renal replacement therapy during 
the trial (n=161)  – lower sodium bicarbonate cost 
  
b) Complete cases over 24 months follow-up and all participants starting renal replacement therapy during 
the trial (n=161)  – lower inpatient stay cost 
  
c) Complete cases over 24 months follow-up and all participants starting renal replacement therapy during 
the trial (n=159)  – ICECAP value 
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NA 
d) Complete cases over 24 months follow-up and all participants starting renal replacement therapy during 
the trial (n=161)  – lower dialysis cost 
  
e) Complete cases over 24 months follow-up and all participants starting renal replacement therapy during the 
trial (n=161)  – higher dialysis cost 
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